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Abstract. This review focuses on research in epidemiology, neuropathology, molecular biology, and genetics regarding the
hypothesis that pathogens interact with susceptibility genes and are causative in sporadic Alzheimer’s disease (AD). Sporadic
AD is a complex multifactorial neurodegenerative disease with evidence indicating coexisting multi-pathogen and inflamma-
tory etiologies. There are significant associations between AD and various pathogens, including Herpes simplex virus type 1
(HSV-1), Cytomegalovirus, and other Herpesviridae, Chlamydophila pneumoniae, spirochetes, Helicobacter pylori, and various
periodontal pathogens. These pathogens are able to evade destruction by the host immune system, leading to persistent infection.
Bacterial and viral DNA and RNA and bacterial ligands increase the expression of pro-inflammatory molecules and activate
the innate and adaptive immune systems. Evidence demonstrates that pathogens directly and indirectly induce AD pathology,
including amyloid- (A) accumulation, phosphorylation of tau protein, neuronal injury, and apoptosis. Chronic brain infection
with HSV-1, Chlamydophila pneumoniae, and spirochetes results in complex processes that interact to cause a vicious cycle
of uncontrolled neuroinflammation and neurodegeneration. Infections such as Cytomegalovirus, Helicobacter pylori, and peri-
odontal pathogens induce production of systemic pro-inflammatory cytokines that may cross the blood-brain barrier to promote
neurodegeneration. Pathogen-induced inflammation and central nervous system accumulation of A damages the blood-brain
barrier, which contributes to the pathophysiology of AD. Apolipoprotein E4 (ApoE4) enhances brain infiltration by pathogens
including HSV-1 and Chlamydophila pneumoniae. ApoE4 is also associated with an increased pro-inflammatory response by
the immune system. Potential antimicrobial treatments for AD are discussed, including the rationale for antiviral and antibiotic
clinical trials.
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THE ALZHEIMER’S DISEASE PATHOGEN
HYPOTHESIS
Alzheimer’s disease (AD) is an inflammatory brain
disease that affects 20 million people worldwide and
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the incidence is expected to rise. Current medical treat-
ment is not optimal, and thus an effective treatment
is very much needed. The disease is associated with a
combination of environmental agents and genetic influ-
ences leading to inflammation of the brain, neuronal
cell death, and progressive dementia [1].
AD is characterized by two main pathological fea-
tures in the brain: senile plaques and neurofibrillary
tangles (NFTs). Senile plaques are extracellular and are
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predominantly made up of amyloid- (A), a peptide
cleavedfromthemuchlongeramyloid-proteinprecur-
sor(APP).Neurofibrillarytanglesareintracellularand
comprised of abnormally phosphorylated tau protein.
Tau protein is normally associated with microtubules in
neurons, and contributes to AD pathology in its phos-
phorylated state [2].
The AD pathogen hypothesis states that pathogens
act as triggers, interactingwithgenetic factors to initiate
the accumulation and/or formation of A, hyperphos-
phorylated tau proteins, and inflammation in the AD
brain. Herpes simplex virus type 1 (HSV-1) and other
pathogens including Chlamydophila pneumoniae and
Spirochetes are able to infect the brain, evade the host
immune response, and are highly prevalent in the AD
brain [3–9]. In vitro studies and animal models indi-
cate that pathogens induce formation of A, amyloid
plaques,andhyperphosphorylatedtauproteins[10–13].
Pathogens induce a glial inflammatory response and
can directly and indirectly damage and destroy neurons
[14–18]. Significant inflammatory cascades are acti-
vated in the brains of AD patients [19, 20]. Together,
these processes result in neurodegeneration and disease
progression.
This review examines evidence implicating HSV-1
and Cytomegalovirus (CMV), both members of the
Herpesviridae family, and the bacterial pathogens
Chlamydia pneumoniae, spirochetes, periodontal
pathogens, and Helicobacter pylori as causative in
the pathogenesis of AD. Limited evidence is also
presented regarding the Herpesviridae Epstein Barr
Virus (EBV) and Human herpes virus 6 (HHV-6)
as possible contributing factors in AD pathogen-
esis. The multi-pathogen AD hypothesis does not
exclude toxins or other environmental co-factors
that may be involved in the pathogenesis of AD
and are reviewed elsewhere [21]. Pathogens were
selected based on the degree of significant cumulative
evidence identified in an extensive PubMed literature
search.
HERPES SIMPLEX VIRUS TYPE 1
HSV-1 is a neurotropic virus that infects most
humans, attaining 90% prevalence by the sixth decade
of life. Infection is life long, as the virus resides in the
trigeminal ganglia of the peripheral nervous system in
latent form with viral genome but no virions present.
Reactivation leads to viral replication and acute infec-
tions known as herpes labialis, commonly referred to
as cold sores [22].
In 1982, Melvin Ball hypothesized that HSV-1 was
causative in AD. He proposed that latent HSV-1 located
in the trigeminal ganglia could reactivate and ascend
along known nerve pathways into the limbic system
and areas of the brain most affected in AD [23].
Herpes simplex encephalitis and AD affect the same
brain regions, including the frontal lobes, temporal
lobes, and hippocampus. Herpes simplex encephali-
tis survivors show cognitive, memory, and behavioral
decline. Other viruses implicated in neurological
disease include measles in subacute sclerosing panen-
cephalitis and human immunodeficiency virus in
HIV-associated dementia [22]. As with AD, both suba-
cute sclerosing panencephalitis [24] and HIV infection
[25] are associated with the formation of phosphory-
lated tau protein and NFTs in the brain.
EPIDEMIOLOGICAL STUDIES: HSV-1
HUMORAL RESPONSE, COGNITIVE
DECLINE, AND AD
Epidemiological studies show an association
between viral infectious burden (IB) and cognitive
decline. IB is defined as a composite serological mea-
sureofexposure tocommonpathogens[27].Strandberg
et al. measured seropositivity to HSV-1, HSV-2, CMV,
Chlamydiapneumoniae, andMycoplasmapneumoniae
in 383 elderly patients with cardiovascular disease.
Assessments including the Mini-Mental Status Exam-
ination (MMSE) and the Clinical Dementia Rating
were used to define cognitive impairment. Having three
positive viral titers was associated with a 2.5 times
higher risk for cognitive impairment after 12 months
[26]. Katan et al. [27] found an association between
Herpesviridae and cognitive decline using a compos-
ite serologic measure of exposure to both bacterial
(Chlamydia pneumoniae and Helicobacter pylori)
and viral (CMV, HSV-1, and HSV-2) pathogens. As
reviewed by Strandberg, the association was primarily
driven by viral IB [28].
Letenneur et al. studied the risk of developing AD
according to the presence or absence of serum anti-
HSV IgG and IgM antibodies by following 512 elderly
patients initially free of dementia for 14 years. The pres-
ence of anti-HSV IgM antibodies is associated with
primary infection or recent reactivation of HSV. In
contrast, the presence of anti-HSV IgG antibodies indi-
cates lifelong HSV infection [29]. Subjects who were
IgM-positive at baseline showed a significantly higher
risk of developing AD (hazard ratio = 2.55). No signif-
icant increased risk for AD was found in IgG-positive
S.A. Harris and E.A. Harris / Pathogens are Key Causative Factors in Sporadic Alzheimer’s Disease 321
subjects. Among the 43 IgM-positive subjects, only
2 were IgG-negative, which supports recent HSV
reactivation rather than primary infection in most of
the IgM-positive subjects [29]. Similar results were
obtained in a longitudinal study by Lo¨vheim et al.
involving 3,432 elderly patients with a mean follow-up
time of 11.3 years. Baseline increased serum lev-
els of anti-HSV IgM antibodies were associated with
increased risk of developing AD by a factor of 2 [30].
Thus, HSV reactivation, as indicated by the presence
of anti-HSV IgM antibodies, is highly correlated with
incident AD [29, 30].
Kobayashi et al. [31] used the avidity index of
anti-HSV-1 IgG antibodies as an indicator of HSV-1
reactivation. The study, involving patients with amnes-
tic mild cognitive impairment (MCI), AD, and healthy
controls evaluated the relationship between HSV-1
reactivation and the degree of cognitive impairment in
AD. The avidity index is defined as the strength with
which IgG attaches to antigen [32]. HSV reactivation is
characterized by increased levels of high-avidity anti-
HSV IgG antibodies compared to lower levels seen
with initial HSV infections [31]. MMSE and frontal
assessment battery were used to assess cognition. MCI
patients had a higher anti-HSV-1 IgG antibody avidity
index than AD patients or healthy controls implying
that HSV-1 reactivation occurs more frequently in the
MCI group than in the AD group or healthy control
group. Differences in anti-HSV-1 IgG antibody titer
and anti-HSV-1 avidity index readings between the
MCI group and healthy controls also suggests that
reactivation of HSV-1 contributes to progression from
healthy state to MCI [31].
In a longitudinal nested case–control study,
Lo¨vheim et al. measured plasma HSV antibody sam-
ples taken on average 9.6 years before AD diagnosis.
In the 360 patients who developed AD and who had a
follow-up time of 6.6 years or more, past HSV infec-
tion (as indicated by the baseline presence of anti-HSV
IgG antibodies) increased the risk of developing AD
by a factor of 2.25 [33].
Schretlen et al. evaluated cognitive performance
in a group of patients who had been diagnosed with
schizophrenia with an average cohort age of 39 years
[34]. Schizophrenia patients who were HSV-1 IgG
antibody seropositive performed significantly worse on
neuropsychological measures (including psychomo-
tor speed, executive functioning, and explicit verbal
memory) than the combined HSV-1 and HSV-2 IgG
antibody seronegative control group. Patients who
tested seropositive for HSV-1 had decreased grey mat-
ter volume in the anterior cingulate and cerebellum
seen on morphometric magnetic resonance imaging
(MRI) of the brain compared to the HSV-1 seronegative
control group [34]. Poor cognitive test performance
correlated with decreased grey matter volume in some
of the same brain regions that distinguished the patient
subgroups defined by HSV-1 status [34]. Several stud-
ies have confirmed significant cognitive impairment in
HSV-1 IgG seropositive schizophrenia patients com-
pared to HSV-1 IgG seronegative controls with average
cohort ages reported as 38 to 42 years old [35–39].
A causal association between exposure to HSV-1
and increased risk for schizophrenia has not been
proven [34]; however, HSV-1 exposure in this group of
neuropsychiatric patients is associated with cognitive
impairment and provides further supportive evidence
for the role of HSV-1 in cognitive dysfunction.
Higher levels of HSV-1 humoral immune response
appear to play a protective role in the early stages
of AD. Analyses performed with voxel-based mor-
phometric brain MRI in AD patients and healthy
controls indicate the presence of significant correla-
tions between the preservation of cortical bilateral
temporal and orbitofrontal grey matter volumes with
higher HSV-1 IgG serum antibody titers [40].
HSV-1 IS HIGHLY PREVALENT IN
ELDERLY BRAINS
Polymerase chain reaction (PCR) methods used by
Jamieson et al. to detect HSV-1 DNA in autopsy brain
specimens confirmed that latent HSV-1 is present in a
high proportion (70–100%) of sporadic AD and elderly
normal brains [4]. HSV-1 was found in brain areas most
affected by AD, namely the temporal cortices, frontal
cortices, and hippocampus. The Jamieson et al. find-
ings have been confirmed in several studies (Table 1)
[41]. The virus was found in very low proportions
in younger brains [42]. In addition, Mori et al. [43]
and Rodriguez et al. [44] used PCR to identify HSV-1
DNA in AD brains. PCR improves sensitivity in HSV-1
detection when compared to previously applied tech-
niques such as in situ hybridization [4]. Some PCR
studies had lower detection rates than others, perhaps
due to a lower prevalence of HSV-1 infection in Japan
[45] or age not having been taken into account. For
unknown reasons, Hemling et al. [46] and Marquis
et al. [47] detected HSV-1 DNA in a very low pro-
portion of brains.
Intrathecal HSV-1 IgG was found in 52% of an
AD cohort and 69% of the age-matched normal group
using enzyme-linked immunosorbent assay (ELISA)
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testing [48]. This data confirms the aforementioned
PCR finding that HSV-1 DNA sequences are present
in many elderly brains as a whole functional HSV-1
genome and provides evidence that the virus replicates
in the brain [48].
HSV-1 IN THE BRAIN OF APOE-ε4 ALLELE
CARRIERS INCREASES THE RISK FOR AD
Additional evidence for HSV-1 in AD involves the
type-4 allele of the apolipoprotein E gene, known as
APOE-4 or APOE4. A significantly increased risk for
sporadic AD is associated with the presence of both
HSV-1 in brain and carriage of the APOE-4 allele
[49]. As shown in a study of AD postmortem brains by
Itzhaki et al. [49] and confirmed by Lin et al. [50], nei-
ther HSV-1 nor the APOE-4 allele alone was found
to be a risk factor for AD. However, the combination
of HSV-1 with the APOE-4 allele increased the risk
for AD by a factor of 12 [50]. HSV-1 in the brains
of APOE-4 allele carriers accounted for over half of
AD patients in the study (Table 2) [49]. The propor-
tion of HSV-1 positive elderly controls was similar to
that of HSV-1 positive AD patients, indicating that
the AD brain is not predisposed to HSV-1 infection.
Few HSV-1 positive elderly controls were positive for
the APOE-4 allele, indicating that APOE-4 allele
carriers are not predisposed to HSV-1 infection [49].
Itzhaki’s results were later confirmed by Itabashi and
colleagues [45].
Table 1
Studies that have detected HSV-1 DNA using PCR in brain tissue from patients with AD and controls (non-neurological cases)
Study Primers used for PCR Area of brain sample HSV-1 DNA-positive individuals
AD n (%) Controls n (%)
Jamieson et al. [4] TK Temp, frontal cortex, hippocampus 8 (100) 6 (100)
Jamieson et al. [42] TK Temp, frontal cortex, hippocampus 21 (67) 15 (60)
Baringer and Pisani [271] Various Various NR 40 (35)
Gordon et al. [272] Various Hippocampus and frontal cortex 30 (27)
Itabashi et al. [45] gD Temporal and frontal cortex 46 (30) 23 (22)
Itzhaki et al. [49] TK Frontal and temporal cortex 46 (67) 44 (64)
Lin et al. [50] TK Frontal and temporal cortex 61 (74) 48 (63)
Bertrand et al. [273] gD Various 98 (75) 57 (72)
Cheon et al. [274] gD Frontal cortex 10 (100) 10 (100)
HSV-1, herpes simples virus type 1; AD, Alzheimer’s disease; PCR, polymerase chain reaction; gD, glycoprotein D protein; TK, thymidine
kinase; NR, not Reported. Table adapted from Itzhaki R (2004) Herpes simplex virus type 1, apolipoprotein E and Alzheimer’ disease. Herpes
11(Suppl 2), 77A-82A. [41] Reprinted with permission from Ruth Itzhaki.
Table 2
APOE genotypes of Alzheimer’s disease patients and aged non-Alzheimer’s disease patients positive
or negative for Herpes Simplex Virus Type 1 in all brain regions
Overall data for all brain regions
Non-AD (n = 44) AD (n = 46)
HSV1+ HSV1– Total HSV1+ HSV1– Total
Genotype
2/ 2 0 0 0 0 0 0
2/ 3 1 3 4 2 1 3
2/ 4 0 0 0 0 0 0
3/ 3 25 11 36 5 7 12
3/ 4 2 2 4 20 2 22
4/ 4 0 0 0 9 0 9
Allele number
2 1 3 4 2 1 3
3 53 27 80 32 17 49
4 2 2 4 38 2 40
APOE- 4 3.6% 6.3% 4.5% 52.8% 10.0% 43.4%
HSV-1 in brains of APOE-4 allele carriers accounts for over 50% of AD brains with testing done postmortem.
Table from Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997) Herpes simplex virus type
1 in brain and risk of Alzheimer’s disease. Lancet 349, 241-244 [49]. Copyright 1997. Reprinted with permission
from Elsevier and Ruth Itzhaki.
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APOLIPOPROTEIN E INFLUENCES HSV-1
VIRAL LOAD IN ANIMAL BRAIN STUDIES
Apolipoprotein E dosage and the presence ofAPOE-
4 determine latent HSV-1 DNA concentrations in
the mouse brain [51]. Burgos and colleagues inoc-
ulated mice with HSV-1 and measured brain viral
DNA concentrations. Thirty-seven days after infection,
the HSV-1 brain DNA concentrations for APOE+/+
wild-type mice were 13.7 times greater than those of
APOE–/– knockout mice. HSV-1 brain DNA concen-
trations for human APOE4 transgenic mice were 13.6
times greater than those of APOE3 mice. Apolipopro-
tein E4 appeared to facilitate HSV-1 latency in the
brain much more than apolipoprotein E3, and APOE
dosage correlated directly with the concentration of
HSV-1 in the brain [51]. Guzman-Sanchez and col-
laborators later confirmed that apolipoprotein interacts
with HSV-1 in animal models to increase viral load in
the brain. 2-month-old wild-type and APOE knock-out
mice were infected with HSV-1 and followed for 16
months. Viral load was found to increase with age. Viral
load in the brains of aged APOE+/+ wild-type female
mice was 43 times that seen in knock-out APOE–/–
male mice. Although no neuropathological or brain
MRI morphological differences were detected between
18-month-old infected mice when compared to con-
trols, the central nervous system (CNS) HSV-1 infected
miceshowedassociatedmemorydeficitandreductionin
metabolic indicators of CNS health [52]. These animal
studies which associate APOE4 with increased HSV-1
viral loadinthebrainmayrelatetoItzhaki’shumanpost-
mortem study, indicating that the combined presence of
HSV-1 in brain and carriage of the APOE-4 allele are
involved in the pathogenesis of AD [49].
GENOME-WIDE ASSOCIATION STUDIES
Two genome-wide association studies identified
APOE, complement receptor 1 (CR1), clusterin (CLU),
and phosphatidylinositol binding clathrin assembly
protein (PICALM) as major susceptibility genes in AD
[53]. These susceptibility genes are associated with the
HSV life cycle, and relate either directly or indirectly
to cellular entry, intracellular transport, nuclear egress,
APP processing, and A processing [53].
AD AMYLOID PLAQUES CONTAIN HSV-1
DNA
HSV-1 coexists with A in AD amyloid plaques
[3]. Using in situ PCR to detect HSV-1 DNA and
G
Fig. 1. Co-localization of HSV-1 DNA and amyloid- in AD
plaques. A strong co-localization showing HSV-1 DNA (brown
staining using PCR) and amyloid plaque (blue staining using
immunohistochemistry) in a postmortem AD brain (G). Greater than
90% AD plaques contained viral DNA. Scale bar = 50m. Figure
from Wozniak, MA, Mee AP, Itzhaki RF (2009) Herpes simplex
virus type 1 DNA is located within Alzheimer’s disease amyloid
plaques. J Pathol 217, 131-138 [3]. Copyright 2008. Reprinted with
permission from John Wiley and Sons, Inc. and Ruth Itzhaki.
immunohistochemistry or thioflavin S staining to
detect amyloid plaques, Wozniak and coworkers dis-
covered a striking co-localization of HSV-1 DNA and
Awithin senile plaques in postmortem brains (Fig. 1)
[3]. In AD brains, 90% of the plaques contained HSV-1
DNA and 72% of the total brain HSV-1 DNA was asso-
ciated with plaques. The HSV-1 DNA associated with
plaques was much lower in aged normal brains than in
AD brains (p < 0.001) [3]. The co-localization of HSV-
1 DNA and Awithin amyloid plaques in the AD brain
places HSV-1 in direct juxtaposition with a highly sig-
nificant AD biomarker and suggests a significant role
for HSV-1 in AD pathogenesis.
IN VITRO AND ANIMAL STUDIES: HSV-1
INFECTION INDUCES ELEVATED LEVELS
OF A AND P-TAU
Human cultured neuroblastoma cells infected with
HSV-1 in vitro produce A42 and A40, and increased
amounts of the enzymes-site APP-cleaving enzyme
(BACE-1) and nicastrin (a component of the -
secretase enzyme) [10]. Both enzymes are involved in
cleavage of the APP to produce A. Rapid reduction
of APP and a dramatic increase in A42 and A40
is seen in HSV-1-infected neuronal cell cultures [10].
Rat cortical neurons challenged with HSV-1 demon-
strate hyperexcitability, membrane depolarization, and
increased intracellular calcium levels with enhanced
calcium dependent-APP phosphorylation and intra-
cellular accumulation of A42 [54]. Animal models
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also support HSV-1 as causative in the formation of A.
Mouse brain infected with HSV-1 produced marked
increases in A42 five days post-intranasal infection
when compared to uninfected controls [10]. These
studies indicate that HSV-1 exposure to neuronal cells
results in cellular production of A.
HSV-1 is able to induce tau phosphorylation, thus
linking HSV-1 to the formation of another abnor-
mal protein found in AD brains. Neuroblastoma cells
infected with HSV-1 produce hyperphosphorylated
tau protein and increased amounts of the enzymes
that phosphorylate tau protein including glycogen
synthase kinase-3 (GSK-3) and protein kinase A
[11]. Alvarez et al. demonstrated accumulation of
hyperphosphylated tau protein within the nucleus of
HSV-1 infected neuroblastoma cells [55]. Zambrano
et al. showed that HSV-1 infection of murine neu-
ronal cultures results in tau hyperphosphorylation and
alterations in the microtubule dynamics of the neu-
ronal cytoskeleton [56]. The ability of HSV-1 to induce
phosphorylation of tau proteins in neuronal cells is
significant because p-tau proteins contribute to the for-
mation of NFTs in AD brains [2].
ADDITIONAL MOLECULAR EVIDENCE
AND CELLULAR MECHANISMS
RELATING HSV-1 TO AD
Additional studies show a structural link between
HSV-1 and A. A34-42 is 67% identical to the HSV-1
envelopeproteinglycoproteinB(gB)peptidesequence,
indicating peptide homology [57]. Synthetic peptides
derived from the HSV-1 gB fragment self-assemble
into thioflavin-positivefibrilsandform-pleatedsheets
thatareultrastucturally indistinguishable fromA [57].
The gB fragment accelerates in vitro formation of A
fibrils that are toxic to primary cortical neurons at a dose
comparable to A [57].
HSV-1 travels inside the neuronal cytoplasm in asso-
ciation with APP [58]. In squid axons, HSV-1 travels
with APP during fast anterograde transport from the
nerve cell body down the axon [59]. The virus interferes
with APP processing in HSV-1-infected neuronal
cells, reducing the level of APP and increasing the
level of a 55 kDa C-terminal APP fragment con-
taining A [60]. De Chiara et al. found that HSV-1
infection of neuroblastoma cells and rat cortical neu-
rons induces multiple cleavages of APP with resultant
neurotoxic intra and extracellular APP fragments that
comprise portions of A. Components of the amyloido-
genic APP processing pathway, including host cell
-secretase, -secretase, and caspase-3 like enzymes,
were shown to be involved in the APP cleavage
process. These findings suggest that repeated HSV-1
reactivation in the presence of other risk factors may
play a co-factorial role in the development of AD [61].
Cheng and colleagues evaluated HSV-1 interactions
with APP using immune-fluorescence, immunogold
electron microscopy, and live cell confocal imaging
to visualize newly synthesized viral particles inside
epithelial cells as they traveled to the cell surface. Cyto-
plasmic HSV-1 particles labeled with green fluorescent
protein co-localized and traveled with APP inside liv-
ing cells. Most intracellular HSV-1 particles interacted
frequently with APP, which facilitated viral transport
while interfering with normal APP transport and dis-
tribution. Intracellular HSV-1 interactions with APP
provide a mechanistic basis for the association between
HSV-1 seropositivity and AD [62].
Santana et al. demonstrated that HSV-1 infection
of neuroblastoma cells induced significant intracel-
lular accumulation of A in autophagosomes and a
marked decrease in A secretion. A failed to fuse
withlysosomesinHSV-1-infectedneuroblastomacells,
indicating the impaired degradation of A localized in
autophagic vesicles [63]. HSV-1 decreases autophagy
using HSV-1 infected cell polypeptide 34.5 (ICP 34.5)
whichblocks theproteinkinaseR(PKR)andeukaryotic
initiating factor 2 (eIF2) signaling pathways [64].
This action inhibits HSV-1 degradation by interfering
with autophagy of the virus [64, 65]. Itzhaki suggests
that this may lead to a decrease in A clearance and an
accumulation of senile plaques in AD [66].
HSV-1 can both block and induce neuronal apop-
tosis. HSV-1 protein ICP34.5 dephosphorylates eIF2
to block both the shutdown of host cell protein synthe-
sis and apoptosis [66, 67]. HSV-1 infection of murine
neuronal cultures results in marked neurite damage and
neuronal apoptosis [56].
HSV-1 INDUCES AD-LIKE
INFLAMMATION AND OXIDATIVE
STRESS
Elevated levels of pro-inflammatory cytokines are
consistently found in the brains of AD patients
[19, 20]. Infection by HSV-1 induces expression of
cytokines and pro-inflammatory molecules, including
interleukin-1 (IL-1), tumor necrosis factor- (TNF-
), IL-6, IL-8, macrophage inflammatory protein 1-
(MIP-1 ), chemokine (C-C motif) ligand 5 (CCL5),
and chemokine CXCL 10 in human microglial cells
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[17]. Persistent cytokine expression occurs in mouse
trigeminal ganglion infected with HSV-1, including
IL-2, IL-6, TNF-, interferon-  (IFN- ), IL-10, and
CCL5 [18]. The direct effects of HSV-1 on neurons
and the host inflammatory response to infection can
lead to oxidative damage due to increased formation
of reactive oxygen and reactive nitrogen species [68].
Interactions between HSV-1 and oxidative stress
promote neurodegenerative processes found in AD.
In HSV-1 infected human neuroblastoma cells, exper-
imentally induced oxidative stress was found to
significantly enhance the accumulation of intracellular
A, inhibit A secretion, and appeared to be mediated
by HSV-1 infection [69]. Oxidative stress also poten-
tiated the accumulation of autophagic compartments
within the cell [69]. HSV-1 interactions with oxida-
tive stress are significant because oxidative damage is
thought to occur early in the pathogenesis of AD [70].
HSV-1 REACTIVATION IN THE BRAIN
Itzhaki points out the lack of methodology for
detecting the hypothesized sub-clinical limited reac-
tivation of HSV-1 in localized areas of the brain in
AD patients [32]. This contrasts with clinically appar-
ent acute HSV encephalitis, where detection of HSV-1
DNA in cerebrospinal fluid (CSF) is commonly used
for diagnosis [32]. Mild forms of HSV-1 encephali-
tis in humans have been reported [71, 72]. These
patients usually have less severe symptomatology and
good prognoses when compared to patients with severe
diffuse HSV-1 meningoencephalitis. Klapper et al.
suggest that sub-acute HSV-1 encephalitis may be a
more common and often missed sub-clinical presenta-
tion of the disease [71].
Peter and collaborators reviewed 3,200 randomly
selected CSF specimens submitted for HSV testing and
found a total of 62 HSV positive specimens. HSV-2 was
detected more often than HSV-1 (36:26). However, the
HSV-2: HSV-1 ratio reversed in the patients over age
60 with HSV-1 being more prominent (3:13). Female
patients who were positive for HSV-1 predominated
in the over-70 age group (10 female and 1 male with
90% of females positive for HSV-1). This study shows
predominance in the reactivation of HSV-1 rather than
HSV-2 in older females, a group known for having a
higher incidence of AD [73].
Saldanha et al. found that HSV-1 reactivates in
the brains of immunosuppressed patients. HSV-1
DNA was detected by in situ hybridization in post-
mortem frontal and temporal lobe human brain samples
from immunosuppressed leukemia patients who were
seropositive for HSV-1. HSV-1 DNA was not found in
HSV-1 seronegative patients or in those who had not
been immunosuppressed [74].
The reactivation rate of HSV-1 in the human brain is
not known; however, animal and human studies involv-
ing the CNS and peripheral nervous system suggest
that periodic sub-clinical reactivation may occur with
subsequent immune response and neurodegeneration.
Kaufmanetal.measuredtherateofasymptomaticHSV-
1 reactivation and shedding in human tears from normal
adults without signs of ocular herpetic disease. 74% of
the 50 subjects were positive for HSV IgG by ELISA.
49/50 (98%) of subjects shed HSV-1 DNA at least one
time during the course of the 30-day study [75].
Margolis and colleagues described spontaneous
molecular reactivation of HSV-1 with viral protein
expression, positive HSV-1 antigen staining, and infec-
tious virus found in 6% of “latently” infected murine
sensory ganglia 37 days post ocular infection [76].
Using in situ hybridization and immunohistochem-
istry, Feldman et al. found that HSV-1 spontaneous
reactivation occurred in one neuron per 10 HSV-1
latently infected mouse trigeminal ganglia tested [77].
These neurons were surrounded by focal white cell
infiltrate, indicating an inflammatory response. The
authors estimate that this is equivalent to one neuron
expressing high-level productive cycle viral genes in
each ganglion every 10 days [77].
Asymptomatic reactivation of HSV-1 occurs in vivo
in the CNS of mice and is associated with pro-
duction of markers of neurodegeneration found in
AD [78]. HSV-1 reactivation from the asymptomatic
latent phase, was demonstrated by detection of viral
ICP4 protein in the trigeminal ganglion and cerebral
cortex of mice 60 days post-infection. Reactivation
was accompanied by upregulation of both markers
of neuroinflammation [(toll-like receptor (TLR)-4,
interferon /, and phosphorylated interferon regula-
tory factor 3 (p-IRF3)] and early neurodegeneration
(phospho-tau and caspase-3 cleaved tau proteins) [78].
These findings support the hypothesis that recurrent
HSV-1 CNS reactivation could result in AD associated
neurodegenerative processes.
PROPOSED MECHANISM OF HSV-1
PATHOGENESIS IN AD
The above data and studies support the hypothesis
that HSV-1 in combination with APOE-ε4 allele car-
riage is a major cause of sporadic AD. As proposed
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by Itzhaki, this highly prevalent virus reactivates and
enters the brain in older age by way of the peripheral
nervous system or the olfactory route. HSV-1 becomes
latent in the brain, but periodically reactivates in asso-
ciation with systemic infection, immunosuppression,
or other stressors. The reactivated virus causes limited
local damage via direct viral action and through inflam-
matory and oxidative effects. This leads to deposition
of A and abnormal phosphorylation of tau, which
eventually forms amyloid plaques and NFTs. Defec-
tive autophagy due to aging and viral ICP34.5 action
prevents degradation of HSV-1 and reduces the degra-
dation of A and phosphorylated tau protein. This
results in decreased clearance of these proteins [66,
79, 80].
CYTOMEGALOVIRUS AND OTHER
HERPESVIRDAE
Cytomegalovirus
CMV is a -herpes virus prevalent in humans
causing persistent lifelong asymptomatic infection in
the immunocompetent host. Primary infection usu-
ally occurs early in life and is asymptomatic but
occasionally causes a self-limiting mononucleosis-like
syndrome [81]. CMV seropositivity in the human
population ranges from 20%–100% depending on
socioeconomic status and age [82]. The virus resides
in the myeloid cell compartment, remaining latent
in monocytes [83], but has tropism for numerous
cell types such as endothelial cells, epithelial cells,
fibroblasts, smooth muscle cells, neuronal cells, hepa-
tocytes, trophoblasts, macrophages, and dendritic cells
[81]. As with other members of the Herpesviridae
family, CMV may reactivate under stress condi-
tions or other stimuli. Other diseases associated with
CMV infection in normal hosts include Guillain-Barre
syndrome, meningoencephalitis, hemolytic anemia,
and thrombocytopenia [81]. CNS infection by CMV
in immunocompetent patients is rare. Most CMV
brain infections occur in those who are immunocom-
promised, such as HIV-infected patients, transplant
recipients, and infants with congenital CMV disease
contracted in utero [82].
Epidemiological studies: CMV humoral response,
cognitive decline, and AD
Several studies have shown an association between
CMV infection and increased risk of both cognitive
impairment and development of AD. Aiello et al. found
that individuals with higher levels of IgG antibody to
CMV at baseline experienced a more rapid rate of cog-
nitive decline over a 4-year study period than those with
lower levels [84]. Strandberg et al. [26] and Katan et al.
[27] found that CMV was one of the viruses from the
Herpesviridae family associated with cognitive decline
as discussed in the HSV-1 section above. Carbone et al.
studied a group of elderly patients and found baseline
CMV IgG antibody levels to be significantly increased
in patients who developed clinical AD over a 5-year
follow-up period compared to patients who remained
cognitively healthy [85]. Barnes et al. followed 849
participants and found that baseline CMV seroposi-
tivity doubled the risk of developing clinical AD over
a 5-year follow-up period and noted a faster rate of
decline in global cognition [86].
Tarter et al. studied cognitive impairment in var-
ious age groups in relation to CMV and HSV-1
seropositivity. Among children (ages 6–16 years),
HSV-1 seropositivity was associated with lower read-
ing and spatial reasoning test scores. Both HSV-1 and
CMV seropositivity in middle–aged adults (ages 20–59
years) was associated with impaired coding speed.
CMV seropositivity was also associated with impaired
middle-aged learning and recall. Among older adults,
HSV-1 seropositivity was associated with immediate
memory impairment. The data indicated that HSV-1
may have a life course effect on cognition across all
age groups, while CMV appeared to adversely affect
cognition specifically in the middle aged. The authors
suggest that individuals who acquire infection with
these Herpesviridae earlier in life with more reacti-
vations and subsequent immune activation may be at
greater risk for developing social disparities in cogni-
tion, educational attainment, and social mobility across
the life course [87].
Prevalence of CMV in the AD Brain
Data does not indicate a definitive direct infiltrative
CNS role for CMV in AD. Using PCR, Lin et al. found
CMV present in 16/45 (35.6%) of postmortem AD
brains compared with 10/29 (34.5%) of non-AD con-
trols, which was not statistically significant [88]. The
authors point out that these values may be artificially
high due to the possibility of CMV residing in lympho-
cytes within blood vessels rather than brain cells. In a
more recent 2013 study, 93 AD brains were tested for
CMV DNA using nested PCR and all samples were
negative for CMV [85]. In contrast, Lin et al. found
CMV in a very high proportion of postmortem vas-
cular dementia brains [89]. CMV was found in 14/15
(93%) of brains from subjects who had been diagnosed
with vascular dementia and was present in only 10/29
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(34%) of age-matched normal controls. The results
were statistically significant and suggest a possible role
for CMV in vascular dementia [89].
CMV and immunosenescence: Impairment of the
elderly immune system
CMV appears to be a strong causative factor in
the development of immunosenescence by adversely
affecting T cell immunity with resultant immune dys-
regulation and impairment in the elderly [90]. CMV
has been implicated in T cell oligoclonal expansions,
altered phenotypes and function of CMV specific
CD8+ T cells, and decrease in the naı¨ve and early mem-
ory T cell pool seen in the elderly [90]. Koch et al.
reviews evidence for CMV involvement in immuno-
senescence and suggests that the long-term attempt of
the T-cell immune system to keep CMV from spread-
ing results in reduction of the naı¨ve T-cell pool, leading
to deficits in the immunological response to new anti-
gens in the aged [90]. Clonal expansions of CD8+ T
cells directed against another Herpes virus, EBV, are
also seen in the aged population [91].
Increased reactivation of CMV and other
herpesviridae in the elderly
Using molecular and serological techniques, Stowe
et al. found significant increases in reactivation of
CMV and EBV in elderly subjects compared to
younger subjects. Increases in CMV DNA in urine
and Epstein Barr viral load in peripheral blood were
demonstrated. In addition, elevated levels of CD8+ T
cells directed against CMV and EBV were found in
the elderly group. The authors concluded that the aged
immune system is no longer able to control EBV and
CMV reactivation, resulting in chronic infection and
age-related clonal expansions of CD8+ T cells directed
against EBV and CMV [91].
Evidence suggests that CMV infection may
adversely influence the immune response, allowing for
increased HSV-1 reactivation. Stowe et al. measured
serum CMV and HSV-1 antibody levels in 1,454 mul-
tiethnic subjects. Higher HSV-1 IgG serum antibody
levels, which presumably reflect higher rates of HSV
reactivation, were more common in CMV seropositive
subjects. Elevated antibody titers to latent HSV-l were
significantly associated with both CMV seropositivity
and high CMV antibody levels. Increases in HSV-1
antibodies by age occurred in CMV seropositive indi-
viduals but not CMV seronegative subjects. Among
CMV seropositive subjects, increases in HSV-1 anti-
bodies by age were only found in individuals with
low CMV antibody levels, as those with high CMV
antibodies already exhibited elevated HSV-1 antibod-
ies. The results suggest chronic CMV infection is able
to accelerate immunosenescence, leading to immune
dysregulation with increased HSV-1 reactivation [92].
CMV is associated with elevated IFN-γ that
associates with AD
CMV-specific CD8+ T cells have been shown to pro-
duce increased amounts of pro-inflammatory IFN-
and very low levels of anti-inflammatory cytokines IL-
2 and IL-4 with a potential shift to a pro-inflammatory
cytokine profile in the elderly [93]. Westman et al.
measured the cytokine response of peripheral blood
mononuclear cells (PBMCs) from CMV seropositive
and seronegative AD patients. PBMCs from CMV
seropositive AD patients challenged by CMV antigens
produced increased amounts of IFN- compared with
CMV seronegative AD patients and CMV seropositive
non-demented controls [94]. The authors suggest CMV
acts as an inflammatory promoter in AD immunology.
In the Rush AD Center Religious Orders Study,
Lurain and colleagues studied a clinical-pathological
community cohort by evaluating CMV serum antibody
levels, CSF IFN- levels, cryopreserved lymphocytes,
and brain pathology from deceased and autopsied sub-
jects [82]. CMV-specific serum IgG antibody levels
were significantly associated with NFTs. CSF IFN-
was detected in greater than 80% of CMV seropos-
itive but not in CMV seronegative subjects. In the
CMV seropositive subjects, CSF IFN- levels were
associated with NFTs. Therefore, this study showed
an association between CMV seropositivity and detec-
tion of IFN- in CSF, which in turn was associated with
AD pathology in the form of NFTs. In addition, the
percentage of senescent T cells (CD28- CD57+) from
the peripheral circulation was significantly higher for
CMV-seropositive as compared to CMV-seronegative
subjects [82]. This study did not prove CMV pres-
ence in the brain of AD patients as CMV intrathecal
antibody levels were not measured, and thus viral repli-
cation of CMV within the brain was not substantiated
[95]. However, results from the Lurain et al. study sup-
port an association between CMV infection and the
development of AD with CMV-induced inflammation
as one potential mechanism for this association [96].
Human herpesvirus 6
HHV-6 is a neurotropic virus and exists in 2 forms:
type A and type B. The HHV-6A variant is considered
more neurotropic than type B [97]. HHV-6B pri-
mary infection is the cause of the common childhood
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illness exanthem subitum, which is also known as
roseola infantum or sixth disease. This illness affects
infants and typically presents with self-limiting fever
followed by a maculopapular rash. Febrile seizures
occur in 10–15% of cases, and severe CNS compli-
cations have been reported in rare cases. The virus
is highly seroprevalent, affecting nearly 100% of the
population by age 3 [98]. HHV-6 can cause menin-
goencephalitis, and has been associated with multiple
sclerosis, seizures, and temporal lobe epilepsy [99].
HHV-6 establishes latency in the brain and can reacti-
vate under conditions of immunosuppression [97].
HHV-6 has been found in the brains of AD patients
in various studies using PCR; however, increased inci-
dence in AD patients versus controls has not been
shown with consistent statistical significance. Lin and
collaborators studied 50 postmortem AD brains and
found HHV-6 in 72% of frontal and temporal cor-
tex samples versus 40% of age-matched normal brain
samples, which was statistically significant [88]. In
the HHV-6 positive brains, 59% (17/29) had type B
alone, 3% had type A alone, and 38% (11/29) had both
types. No additional increased risk for AD was found
in APOE-ε4 carriers who were HHV-6 positive. The
authors reasoned that HHV-6 might enhance the dam-
age caused by HSV-1 and APOE-ε4 in AD. However,
it was not possible to exclude HHV-6 as an opportunis-
tic secondary infection, or the possibility that HHV-6
DNA is present within leucocytes within the brain vas-
culature [88]. Hemling et al. examined autopsy brain
samples from hippocampus, temporal cortex, frontal
cortex, and anterior cingulate gyrus, and found HHV-6
in 88% of AD and 87.5% of normal controls, indicat-
ing no significant difference between the two groups.
However, the number of specimens from the different
brain regions tested was not specified [46]. Carbone
and colleagues found HHV-6 in 17.3 % of frontal cor-
tex samples from postmortem AD patients using qPCR
with no APOE-ε4 carrier association found. The same
group found that baseline HHV-6 DNA positivity in
peripheral blood leukocytes (PBLs) was significantly
associated with cognitive decline and development of
AD at 5-year follow-up [85].
Epstein barr virus
EBV is a Herpes virus that infects 95% of humans
early in life resulting in lifelong latent asymptomatic
infection residing in B-lymphocytes [100]. Primary
infection of the oropharynx often occurs during child-
hood and is generally asymptomatic, although the
virus does cause acute infectious mononucleosis in
a minority of immune competent subjects. Intermit-
tent reactivation of the virus occurs throughout life
within B cells, involving a lytic cycle at mucosal
sites with low levels of asymptomatic viral shed-
ding [101]. EBV is causatively linked to Hodgkin
lymphoma, Burkitt lymphoma, and nasopharyngeal
carcinoma [102, 103]. EBV is also associated with
neurological diseases including encephalitis, myelitis,
mononeuritis [104,105], and multiple sclerosis [106].
Although EBV-related AD data is limited, the virus
may be a risk factor for development AD. Carbone
et al. measured EBV DNA in PBLs and postmortem
brain samples from a group of AD subjects and non-
AD controls. 45% of PBLs were EBV DNA positive
in AD patients compared to 31% of controls, which
was statistically significant. Using qPCR, only 6% of
AD brains were EBV DNA positive with all of these
subjects found to be APOE-4 positive. The same
researchers found that baseline EBV DNA positive
PBLs and serum IgG levels for EBV antigens were
significantly increased in a group of elderly individuals
who developed AD during a subsequent 5-year follow-
up period [85]. Thus, positive IgG levels for EBV and
peripheral viral infection involving PBLs with either
EBV or HHV-6 have been associated with increased
risk for AD even though significant infiltrative CNS
presence has not been demonstrated for EBV and has
been equivocal for HHV-6.
Bacterial pathogens
Chlamydophila pneumoniae
C. pneumoniae is an obligate intracellular respira-
tory pathogen that can persist as a chronic infection in
monocytes, macrophages, and other cell types for long
periods of time. Serum antibody prevalence reaches
70% to 80% by 60 to 70 years of age [107]. Evidence
indicates that C. pneumoniae crosses the blood-brain
barrier (BBB) after infection of the respiratory mucosa,
with subsequent hematogenous and lymphatic dis-
semination within infected monocytes [108, 109].
C. pneumoniae is also thought to enter the CNS via
the olfactory route [80]. C. pneumoniae can evade
the mechanisms of bactericidal and oxidative stress,
activate endothelial cells with production of adhesion
molecules, and induce cytokine overproduction [107].
C. pneumoniae has a biphasic life cycle. The ele-
mentary body is spore-like, infectious, metabolically
inactive, and attaches to and enters the host cell. Ele-
mentary bodies then differentiate into reticulate bodies,
which are the reproductive forms. The reticulate bod-
ies undergo binary fission, differentiate back into
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elementary bodies, and exit the cell either by cytol-
ysis with apoptosis or by exocytosis, leaving the cell
intact [107, 110].
C. pneumoniae interferes with the normal apoptotic
signaling pathways and can both inhibit and induce cel-
lular apoptosis. The bacterium can evade the host cell’s
defense mechanisms, and exist as an acute infection or
a chronic persistent infection [107, 111].
Under certain conditions, C. pneumoniae can enter
into a chronic persistent phase characterized by aber-
rant reticulate bodies and other pleomorphic forms
[112]. Metabolic activity is reduced and the organ-
ism is viable but non-cultivable, resulting in a chronic
infection of the host cell [110, 112]. This persistent
phase has been associated with several chronic diseases
including asthma and chronic obstructive pulmonary
disease [112].
Chlamydophila pneumoniae vascular infection
and dissemination into the brain
Vascular infections with C. pneumoniae are associ-
ated with atheromasic plaques and may be an important
factor in the development of brain infection with this
pathogen. Using PCR and IHC techniques, Rassu et al.
detected the presence of C. pneumoniae in atheromasic
plaques sampled from five vascular sites in 18 autopsy
cases (basilar artery, coronary artery, thoracic aorta,
abdominal aorta, and renal arteries). The study showed
100% patient positivity with C. pneumoniae present at
2–5 sites for each case tested [113]. Di Pietro et al.
investigated 19 postmortem cases with past chlamy-
dial vascular infection using immunohistochemistry,
PCR, in situ PCR and in situ reverse transcription PCR.
C. pneumoniae was detected in the brain tissue of 16
out of 19 subjects (84.2%) who also had C. pneumo-
niae vascular infection. The organism was not detected
in the brains of control subjects who were negative for
C. pneumoniae vascular infection (p = 0.0002) [114].
These results provide evidence that a C. pneumoniae
vascular infection can disseminate to the brain.
Prevalence of Chlamydophila pneumoniae in the
AD brain
Balin et al. used PCR to identify C. pneumoniae
in 17/19 (90%) of AD postmortem brain samples,
and in only 1/19 (5%) of control brain samples,
suggesting that infection with the organism is a
risk factor for AD [6]. The results were confirmed
using multiple methodologies. Electron microscopy
and immunoelectron-microscopy studies identified
chlamydial elementary and reticulate bodies in affected
AD brain regions. C. pneumoniae was present in
areas of the brain showing the typical AD neu-
ropathology. Immunohistochemical tests on AD brains
showed C. pneumoniae within pericytes, microglia,
and astroglia. Reverse transcription (RT)-PCR assays
using RNA from affected areas of AD brains con-
firmed the presence of transcripts from two important
C. pneumoniae genes not seen in controls. Cultures
were strongly positive forC. pneumoniae from a subset
of affected AD brain tissues and negative in controls.
C. pneumoniae was present, viable, and transcription-
(b)
(d) (e)
Fig. 2. Images demonstrating Chlamydophila pneumoniae in AD
brain tissue by in situ hybridization. Figure (b) demonstrates
C. pneumoniae from the hippocampus of an AD brain by in situ
hybridization. Figures (d) and (e) show photographic enlargement
of cells harboring C. pneumoniae inclusions identified in AD brain
tissue. Arrows indicate the signal for C. pneumoniae. Image (b) was
obtained using a x40 objective. Figure from Ge´rard HC, Dreses-
Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH
2nd, Bordayo EZ, Whittum Hudson JA, Hudson AP (2006) Chlamy-
dophila (Chlamydia) pneumoniae in the Alzheimer’s brain. FEMS
ImmunolMedMicrobiol 48, 355-366 [7]. Copyright 2006. Reprinted
with permission from John Wiley and Sons and permission from
Brian Balin.
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ally active in areas of neuropathology in the AD brain
[6]. In addition to the standard morphological forms
of the organism, pleomorphic forms of C. pneumoniae
were later observed on ultrastructural analysis, sug-
gesting an adaptive response and/or persistent state of
infection for these organisms in AD [115]. As reviewed
by Shima [116] and Balin [117], four studies [118–121]
failed to detect significant C. pneumoniae in AD brains
potentially due to sampling error, variable methodolo-
gies, and/or absence of standardized techniques.
Gerard and colleagues found C. pneumoniae in
20/25 (80%) of AD postmortem brain samples and 3/27
(11%) of controls (Fig. 2) [7]. Immunohistochemical
analyses found that neurons, microglia, and astrocytes
all served as host cells for C. pneumoniae [7]. Infected
cells were seen in close proximity to senile neuritic
plaques and NFTs [7]. In situ hybridization analysis
in AD postmortem brains indicates an increase in the
number of C. pneumoniae infected cells in APOE-ε4
carriers [123].
A statistically significant increase in CSF levels of
C. pneumoniae DNA has been found in AD patients
[122]. Miklossy found that combined data from studies
attempting to isolate C. pneumoniae reached statistical
significance in AD brains and AD brains plus CSF
compared to controls (Table 3) [5].
Table 3
Detection of Chlamydophila pneumoniae in Alzheimer’s disease
Material Number Method AD Control Ref
Brain 38 PCR, EM, IHC, 17/19 1/19 [6]
RT-PCR, Cult
Brain 25 PCR, IHC 0/25 [118]
Brain 20 PCR, IHC 0/20 [120]
Brain 20 PCR, Cult 2/15a 1/5a [119]
Brain 21 PCR, ISH 21/21 0/1 [123]
Brain 52 PCR, Cult, 20/25 3/27 [7]
RT-PCR
CSF 104 PCR, Cult 25/57 5/47 [122]
Total Brain 177 p = 4.5 × 10–7, 60/125 5/52
OR = 8.7
CI = 3.1–29.5
Brain 281 p = 9.8 × 10–11, 85/182 10/99
and CSF OR = 7.8
CI = 3.7–17.8
AD, number of AD cases with positive detection/number of AD
cases analyzed: Control, number of control cases with positive
detection/number of control cases analyzed; PCR, polymerase chain
reaction; CSF, cerebrospinal fluid; RT-PCR, reverse transcriptase-
PCR; EM, electron microscopy; Cult, culture; P, exact value of
significance following Fisher test; OR, odds ratio; CI, 95% confi-
dence interval values; IHC, immunohistochemistry. aPositive in at
least one of several samples. Table adapted from Miklossy J (2011)
Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol
Med 13, e30 [5]. Copyright 2011. Reprinted with permission from
Cambridge University Press and Judith Miklossy.
Chlamydophila pneumoniae induces
inﬂammation, Aβ plaque formation,
and neurodegeneration
Increased levels of cytokines IL1-, IL-6 and TNF-
were found in supernatants of C. pneumoniae-infected
murine microglial cells in vitro [124]. Neurons exposed
to the supernatants displayed a significant increase in
apoptosis [124].
C. pneumoniae infection in the brains of BALB/c
mice via the intranasal route induces a significant
increase in A plaques compared with non-infected
mice [12]. Early treatment of infected mice with mox-
ifloxacin decreased the number of A plaques to
levels similar to those seen in uninfected control mice.
Infected untreated mice had 8-9 times more Aplaques
than the antibiotic treatment group [117, 125].
Spirochetes
Spirochetes are Gram-negative, helical bacteria that
possess endoflagella. Spirochetes cause a number
of chronic diseases including syphilis (Treponema
pallidum), Lyme disease (Borrelia burgdorferi), and
periodontal disorders such as gingivitis (oral periodon-
tal Treponema spirochetes such as T. sokranski and T.
pectinovarum) [5]. Spirochetes can invade the brain
and form chronic persistent infections. They are known
to spread by hematogenous dissemination, through the
lymphatic system, and along nerve fibers [126].
Prevalence of spirochetes in AD brain
Spirochetes have been detected using various
methodologies with prevalence approaching 90% in
AD brains (Fig. 3) [5, 126]. The association was sta-
tistically significant in postmortem AD brain studies
of all types of spirochetes combined, oral spirochetes,
and Borrelia burgdorferi. Combined, studies detect-
ing all types of spirochetes and their specific species
indicated a prevalence of 68% (90/131) in AD brains
compared to 8.45% in controls [5]. The spirochete fre-
quency detected in all studies reviewed by Miklossy
was eight times higher in AD brains than in controls [5].
Miklossy’s extensive review of research data regarding
spirochetes and AD indicate a probable causal rela-
tionship between neurospirochetosis and AD based on
Koch’s and Hill’s criteria [126].
Using dark field microscopy, Miklossy identified
spirochetes in blood, CSF, and brain in 14/14 AD
autopsy cases and in 0/13 non-AD controls [9].
In this study, spirochetes were cultured from the
blood of four AD cases. Concurrent silver stained
and anti-APP-immunostained frozen section AD
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Fig. 3. Association of spirochetes with Alzheimer’s disease. The
frequency of spirochetes is significantly higher in the brains of
Alzheimer’s disease patients compared to controls. Graph from Mik-
lossy J (2011) Alzheimer’s disease - a neurospirochetosis. Analysis
of the evidence following Koch’s and Hill’s criteria. J Neuroinﬂam-
mation 8, 90 [126]. Copyright 2011. Reprinted with permission
under the terms of the Creative Commons Attribution License,
(http://creativecommons.org/licenses/by/2.0) and permission from
Judith Miklossy.
brain specimens evaluated with electron microscopy
revealed spirochetes located in areas of AD pathol-
ogy. Immunohistochemistry using a specific antibody
against B. burgdorferi identified spirochetes in senile
plaques, neurons, neuropil threads, and in the lep-
tomeningeal and cortical vessel walls in a patient
with concurrent Lyme disease and AD [9]. Electron
microscopy and atomic force microscopy techniques
have been used to identify spirochetes isolated and
cultured from postmortem AD brains [8]. PCR and
immunohistochemistry identified oral spirochetes in
14/16 AD and 4/18 non-AD postmortem brains (Fig. 4)
[127]. DNA identified within neuropil threads in AD
brains using the florescent dye DAPI revealed a heli-
cally shaped morphology similar to the morphology
and distribution in reference spirochete samples [128].
Spirochetes were detected in the brains of 8/8 post-
mortem AD cases and in the blood samples from five
living AD patients [129]. Using immunohistochemi-
cal techniques, Borrelia antigens (including the outer
surface protein A (OspA) of B. burgdorferi) and Bor-
relia genes were co-localized with A deposits and
NFTs in three AD brains from which B. burgdorferi
Fig. 4. Image of oral spirochetes in Alzheimer’s disease brain. The
oral spirochete T. pectinovorum stained dark blue (arrows) in a
section from the hippocampus from an 84-year-old woman with
Alzheimer’s disease. The section was incubated with monoclonal
antibodies to T. pectinovorum, and binding was disclosed using
biotinylated anti-mouse antibodies and avidin-peroxidase. The pho-
tomicrograph was taken at1000X. Scale bar = 10m. Figure from
Riviere GR, Riviere KH, Smith KS (2002) Molecular and immuno-
logical evidence of oral Treponema in the human brain and their
association with Alzheimer’s disease. Oral Microbiol Immunol 17,
113-118 [127]. Copyright 2002. Reprinted with permission from
John Wiley and Sons, Inc. and George Riviere.
was cultured [130]. Bacterial peptidoglycan has been
immunolocalized to senile plaques and NFTs in autop-
sied brain specimens from 54 AD patients [131, 132].
In addition, peptidoglycan and was found co-localized
with A in AD brains but not in controls [131]. The
synthetic peptide BH (9-10), which corresponds to a
-hairpin segment of the B. burgdorferi OspA protein,
forms amyloid-like fibrils in vitro [133].
B. burgdorferi induces Aβ and p-tau formation,
inﬂammation, and neurodegeneration
In vitro, B. burgdorferi invades mammalian neu-
rons and glial cells to cause an AD-like host cell
reaction. A deposition is induced in vitro by expo-
sure of mammalian neurons, astrocytes, microglial
cells, and brain organotypic cell aggregates to Borre-
lia burgdorferi sensu strictu [13]. Histochemical and
immunohistochemical analysis showed morphological
changes including A plaques with -pleated sheet
conformation and tangles. Intracytoplasmic granules
found in astrocytes were similar to the granulovacuo-
lar degeneration seen in AD neurons [13]. Increases in
APP, A, and hyperphosphorylated tau proteins were
detected by western blot in these cells [13]. Nuclear
fragmentation in rat astrocyte cells exposed to pleo-
morphic and cystic forms of B. burgdorferi suggests
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that the spirochete can cause functional damage and
apoptosis [134].
Exposure of rat glial cells to B. burgdorferi recom-
binant lipidated outer surface protein A (L-OspA)
induces astrocyte proliferation and apoptosis. Astro-
cytes produce IL-6 and TNF- in response to L-OspA
[14].Exvivo stimulation of monkey brain explants with
B. burgdorferi induces the production of cytokines
IL-6, IL-8, IL-1, cox-2, and the chemokine B lym-
phocyte chemoattractant (CXCL13) by glial cells, with
concomitant glial and neuronal apoptosis [16].
Additional periodontal pathogens
In addition to the oral spirochetes discussed above,
Kamer et al. found that both the number of posi-
tive tests for IgG serum antibodies against periodontal
bacteria commonly involved in periodontitis (A. acti-
nomycetemcomitans, P. gingivalis, and T. forsythia)
and plasma TNF- level were elevated in AD patients
compared to normal controls. Both endpoints were
independently associated with AD [135]. Results from
the NHANES III study involving a large community
sample, showed that the extent of periodontal disease,
as measured by gingival bleeding, loss of periodontal
attachment, and loss of teeth, was associated with sig-
nificantly decreased cognitive function in early-, mid-,
and late-adult life [136]. Cognitive testing included the
Symbol Digit substitution and the Serial digit Learn-
ing Tests among patients 20–59 years of age and a
Story Recall test in participants aged 70 years of age or
older. Worse scores on all three measures of oral health
status were significantly associated with poorer perfor-
mance on all three measures of cognitive function after
adjustment for age. Level of education was found to
be an important confounding factor. The authors con-
cluded that poor oral health is associated with impaired
cognitive function throughout adult life [136]. A sep-
arate study from NHANES III showed an association
between high serum antibody levels against P. gingi-
valis and lower cognitive function with delayed verbal
recall and impaired subtraction in subjects greater than
60 years of age [137]. Thus, exposure to oral pathogens
is associated with systemic inflammation, cognitive
decline, and AD.
Helicobacter pylori
H. pylori is a curved spiral Gram-negative bac-
terium which colonizes the gastric mucosa in more
than 50% of humans worldwide. The bacterium causes
gastric disorders including functional dyspepsia,
gastritis, peptic ulcer disease, and gastric cancer
[138, 139]. H. pylori infection is associated with
extra-digestive disorders including idiopathic throm-
bocytopenic purpura, vitamin B12 deficiency, and iron
deficiency anemia [140]. The bacterium is also asso-
ciated with vascular disorders such as atherosclerosis,
ischemic stroke, and coronary artery disease [141].
H. pylori gastric infections may be diagnosed with
non-invasive procedures including urea breath test,
serology, or whole blood antibody testing depending
on clinical circumstances [142]. Diagnostic tests for
H. pylori, which require upper endoscopy with biopsy
sampling of the gastric mucosa, include rapid urease
test, histology, bacterial culture, and polymerase chain
reaction technique [143].
Epidemiological studies: H. pylori infection,
cognitive decline, and AD
Epidemiological studies support an association
between H. pylori infection and both MCI and AD.
Kountouras et al. studied sixty-three patients with
amnestic MCI who underwent upper gastrointestinal
endoscopy with histological and serological test-
ing for H. pylori infection. Significantly increased
H. pylori gastric infection, higher mean serum anti-
H pylori IgG concentrations, and higher plasma total
homocysteine titers were found in MCI patients com-
pared to non-MCI anemic controls [144]. In another
study, Kountouras and colleagues found a significantly
higher rate of histologically proven H. pylori gastric
infection among 50 AD patients compared to thirty
non-AD anemic controls [145]. A longitudinal study
by Roubaud-Baudron et al. followed 603 subjects
who were initially free of dementia and 65 years or
older. Baseline seropositivity for H. pylori IgG anti-
body was associated with a 1.46 times increased risk
for the development of dementia over the 20 year
follow-up period compared to non-infected controls
[146]. In a prospective non-randomized study, Koun-
touras et al. found that AD patients had significantly
higher levels of anti-H. pylori-specific IgG antibod-
ies in CSF and serum than age-matched cognitively
normal controls. The severity of AD, as indicated
by lower MMSE scores, correlated with higher lev-
els of anti-H. pylori IgG antibodies in the CSF of
these patients. The authors concluded that the data
appears to link H. pylori infection to the pathophys-
iology of AD. They could not exclude the passage of
H. pylori IgG and antibodies through an AD-related
dysfunctional blood-CSF barrier to explain their find-
ings [147].
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In vitro and animal models: H. pylori induces
formation of Aβ42 and P-tau
Mouse neuroblastoma N2a cells transfected with
human APP are found to overexpress APP. Incu-
bation of H. pylori filtrate with these cells resulted in
increased production of presenilin-2 (a component of
the gamma secretase enzyme complex) and A42. In
the same study, intraperitoneal injection of H. pylori
filtrate resulted in spatial learning and memory deficits
in rats, abnormal hippocampal dendritic spine matura-
tion, and increased presenilin-2 and A42 in rat brain
hippocampus and cortex [148].
H. pylori filtrate induced significant tau hyperphos-
phorylation at several AD-related tau phosphorylation
sites in mouse neuroblastoma N2a cells through acti-
vation of glycogen synthase kinase-3. In the same
study, intraperitoneal injection of H. pylori filtrate in
rats resulted in significant tau hyperphosphorylation
in hippocampal areas of rat brain. Microglial activa-
tion and elevated brain/plasma cytokine levels were
not found. The authors concluded that soluble exotox-
ins of H. pylori may induce tau hyperphosphorylation
and that H. pylori eradication may be beneficial in the
prevention of tauopathy [149]. These studies provide
evidence which links H. pylori infection with AD-like
A and p-tau pathology.
Potential H. pylori pathogenic mechanisms in AD
Evidence for direct brain infiltration by H. pylori
is lacking, and exactly how a gastrointestinal infection
likeH.pylorimight influence neurodegeneration in AD
is unknown. However, gastric inflammation has been
found in patients infected by H. pylori, with increased
production of IL-1, IL-6, IL-12, IL-18, TNF-, and
IFN- [150]. Lagunes-Servin et al. found thatH. pylori
gastric mucosa infection in children was associated
with upregulation of toll-like receptors TLR2, TLR4,
TLR5, and TLR9, and overproduction of cytokines,
including TNF-, IL-10, and IL-8 [151]. These find-
ings are potentially significant because increased levels
of pro-inflammatory cytokines and TLR-induced cell
signaling cascades are implicated in AD pathogenesis
[19, 20].
As reviewed by Kountouras and collaborators, addi-
tional proposed mechanisms for H. pylori related
AD pathogenesis include: i) influences on neuronal
apoptosis through molecular mimicry, in which homol-
ogous H. pylori epitopes induce humoral and cellular
immune responses, which then cross-react with com-
ponents of nerves; ii) molecular mimicry between
H. pylori and endothelial antigens; iii) mononuclear
cell production of a tissue factor-like pro-coagulant
that converts fibrinogen into fibrin; iv) production
of reactive oxygen species and circulating lipid per-
oxidases; v) platelet activation and aggregation; and
vi) reduced levels of vitamin B12 and folate secondary
to chronic atrophic gastritis, resulting in elevated
serum homocysteine levels and subsequent endothelial
damage and neurodegeneration [144, 152].
NEUROINFLAMMATION, PATHOGENS,
AND NEURODEGENERATION
The innate immune system: Glial cells and the
vicious cycle of inﬂammation
Gao and Hong [1] and Griffin [153] have advanced
the hypothesis that uncontrolled inflammation drives
neurodegenerative disease (Fig. 5) [1]. They pro-
pose that CNS pathological processes are initiated by
environmental insults interacting with genetic suscep-
tibility. Interactions between damaged neurons and
deregulated, over activated microglia create a vicious
self-propagating cycle causing uncontrolled long-term
inflammation and progression of chronic neurodegen-
erative disease [1, 153].
Chronic overexpression of IL-1 is found in AD
brains [20] and has been induced by pathogens in
vitro [17,124] and ex vivo [16]. IL-1 has been
shown to increase neuronal APP production [153,
154], apolipoprotein E levels, and astrocyte-mediated
S100 protein levels [153]. BACE-1 levels in neu-
rons are increased by cytokines [155], oxidative stress
molecules [155], and pathogens such as HSV-1 [10].
Along with -secretase, BACE-1 catalyzes the conver-
sion of APP to A, resulting in elevated levels of toxic
forms of A [155]. A activates microglial RAGE
receptors, which appear to mediate the proinflamma-
tory response to A. Fibrillar A activates microglia
cell surface protein CD36 and scavenger receptors A
and B (SR-A and SR-B). Activation of these recep-
tors induces production of reactive oxygen species by
microglia [156].
The cycle is further accelerated by neuronal injury
and neuron cell membrane breakdown products,
cytosolic compounds, and glutamate excess, which
further activates microglia [1]. There is loss of home-
ostasis from a tightly controlled and regulated process
where anti-inflammatory cytokines are utilized for
tissue repair and recovery of function. The resul-
tant uncontrolled inflammation and amplified cytokine
cycle induces neuronal injury, apoptosis, and chronic
disease progression [1, 153, 157].
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Fig. 5. The vicious cycle of neurodegeneration. Neuroinflammation when controlled is reparative and self-limiting but when uncontrolled forms
a vicious cycle and leads to chronic neurodegeneration. Figure from Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive:
uncontrolled inflammation drives disease progression. Trends Immunol 29, 357-365 [1]. Copyright 2008. Reprinted with permission from
Elsevier and John Hong.
Microglia function as innate immune cells in the
brain [156]. Pattern recognition receptors located on
the microglia cell surface identify pathogen associated
molecular patterns on viruses and bacteria, leading to
microglial production of pro-inflammatory molecules
[5]. Pathogen associated molecular patterns include
lipopolysaccharide (LPS), peptidoglycan, lipoteichoic
acid, flagellin, bacterial lipoprotein, and nucleic acid
structures such as bacterial DNA or viral RNA [5].
Examples of pattern recognition receptors located on
the microglia cell surface include TLRs1-9, scav-
enger receptors (SRA, SRB, Macrophage receptor with
collagenous domain (MARCO), CD36) and receptors
for advanced glycogen end products (RAGE) [156].
Additional receptors include Major histocompatibil-
ity complex II (MHCII), cytokine receptors (CD40)
and chemokine receptors (CCR3, CCR5) [20]. The
NADPH oxidase receptor is a membrane-bound
enzyme that catalyzes the production of superoxide
from oxygen. This receptor is activated in the AD
brain, and is associated with neurodegeneration [156].
Many of these receptors are upregulated in regions
of typical AD brain pathology [19]. Increases in
the levels of pattern recognition receptors in animal
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models and cell cultures are associated with neurode-
generation [19].
Microglia produce pro-inflammatory molecules via
intracellular signalingpathways incell culturesandani-
mal models. For example, pathogens activate microglia
TLRs leading to activation of nuclear factor B, the
mitogen activated protein kinases, and jun kinase.
Pathogens can also induce activation of a second
microglial pathway involving interferon regulatory
factor-3 [5]. These pathways lead to the induction of
inflammatory genes that produce cytokines and other
pro-inflammatory compounds [5].
Microglia and astroglia are consistently found sur-
rounding amyloid plaques in AD brains [157]. Amyloid
deposition causes a microglial-mediated inflammatory
response [19]. Pro-inflammatory molecules have been
shown to be involved in pathways of neuronal apopto-
sis [20]. A stimulated microglia secrete TNF- and
glutamate in vitro, resulting in simultaneous activation
ofneuronalTNF-andN-methyl-D-aspartate(NMDA)
receptors and subsequent neuronal apoptosis [158].
Pro-inflammatory compounds produced by glial
cells and upregulated in AD brains include cytokines
(IL-1, IL-1, IL-6, TNF-), chemokines including
macrophage inflammatory protein-1 and monocyte
chemotactic protein-1, prostaglandins (cox 2), growth
factors such as macrophage colony stimulating fac-
tor, and complement components (C1q, and C1 to C9)
[19, 20]. Additional neurotoxic compounds produced
by activated microglia include superoxide, hydrogen
peroxide, and nitrous oxide [156]. Oxidative stress
(lipid oxidation, protein oxidation, DNA oxidation,
and glycol-oxidation) contributes to neurodegenera-
tion in AD [159]. Associated pathological processes
include endoplasmic reticulum stress associated with
change in endoplasmic reticulum calcium homeostasis
[160, 161], release of free electrons from dysfunctional
mitochondria [162], and formation of reactive oxygen
species [163].
Infection with either HSV-1 [10] or C. pneumo-
niae [12] induces A42 deposits and plaques, and
H. pylori filtrate [148] results in elevated levels of
A42 in animal brain models. In vitro infection by
HSV-1 [10], B. burgdorferi [13], and H. pylori filtrate
[148] induces A deposition in mammalian neuronal
or neuronal/glial cell models.
A has been shown in vitro to be an anti-microbial
peptide against eight specific microorganisms, includ-
ing Escherichia coli, Streptococcus pneumonia, and
Candida albicans. AD whole brain homogenates have
significantly higher antimicrobial activity compared
to age matched non-AD control samples [164]. A42
has shown anti-microbial peptide properties by attenu-
ating HSV-1–induced miRNA-146a levels in human
neuronal-glial cell cultures and significantly reduc-
ing pathological HSV-1 effects on cultured brain cells
[165]. A production may be part of the CNS immune
response to infection with eventual harmful effects to
neurons due to overproduction of A [166].
Evidence supporting the role of the adaptive
immune system in AD
Lynch has proposed that BBB permeability, which is
increased in AD, together with the creation of a chemo-
tactic gradient, leads to infiltration of IFN--producing
T cells into the AD brain [167]. T cell production of
IFN- induces classical microglia activation, which
leads to inflammatory cytokine and chemokine produc-
tion. This in turn results in increased APP processing,
A accumulation, further BBB permeability, and infil-
tration of more T cells, leading to a continuous cycle
of neurodegeneration (Fig. 6) [167].
Resident cells in the brain produce only limited IFN-
 [167]. Under normal conditions, T cell entry into
the CNS is limited and thought to be related to T cell
immuno-surveillance [168, 169]. Significant infiltra-
tion of immune cells does occur in neuroinflammatory
conditions [170] and T cells have been localized in the
brains of AD patients [171–178]. Breakdown of the
BBB (see BBB section below), increased expression
of T cell attractant chemokines such as interferon-
-inducible protein 10 (IP-10), and corresponding
chemokine receptors such as CXCR3 on neuronal cells
have been found in AD brains [179] and may contribute
to infiltration of T cells into the AD brain [167].
T cells can interact with microglia to modulate their
function, as demonstrated by in vitro co-culture experi-
ments[167].RestingmicrogliacellsfromBALB/cmice
developed features of antigen presenting cells, includ-
ing strongly upregulated surface expression of MHCII,
CD40, and CD54 when co-cultured with type 1 T helper
cells (Th1) [180]. Conversely, mouse microglia induce
Th1cells toreleaseIFN-[180].Supernatantsproduced
byallo-antigenandmyelinbasicprotein-specifichuman
pro-inflammatory Th1 T-cell lines augmented expres-
sion of cell surface molecules MHC class II, CD80,
CD86, CD40, and CD54, enhanced the functional
antigen-presenting cell capacity in a mixed lymphocyte
reaction, and increased cytokine/chemokine secretion
(TNF-, IL-6, and CXCL10/IP-10) by CNS-derived
human microglia [181]. Co-culture of A-specific Th1
or Th17 cells and microglia induced pro-inflammatory
cytokine production (IL1-, TNF-, and IL-6) and
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antigenpresentingcellcapacityofmicroglia inamurine
model [182]. IFN- activates murine microglial cells
and results in microglial production of TNF- and
inducible nitric oxide synthase (i-NOS) in vitro [183].
Browne and colleagues investigated the role of A-
specific T cells on A accumulation in transgenic mice
that overexpress APP and presenilin 1 (APP/PS1
mouse model), and found significant infiltration of
T cells in these brains. A-specific CD4+ T cells
were generated by immunization with A and a TLR
agonist and polarized in vitro to Th1-, Th2-, or IL-17-
producing CD4+ T cells. A proportion of these T cells
secreted IFN- or IL-17. These A-specific T cells
were then adoptively transferred to APP/PS1 mice at
6 to 7 months of age. At 5 weeks, Th1 cells, but not
Th2 or IL-17-producing CD4+ T cells had infiltrated
into these brains. Additionally, there was increased
microglial activation and CNS A deposition. All of
these findings were associated with impaired cogni-
tive function. Treatment of the APP/PS1 mice with
an anti-IFN- antibody attenuated the Th1 cell effects.
The authors suggest that the release of IFN- from
infiltrating Th1 cells significantly accelerates mark-
ers of diseases in an animal model of AD [184].
Murphy et al. demonstrated that murine Th17 and
CD4+ lymphocytes, which produce IL-17 and IFN-,
induce microglial production of IL-1, IL-6, and TNF-
 in experimental autoimmune encephalomyelitis, the
animal model of multiple sclerosis [185]. The combi-
nation of IFN- and TNF- has been shown to induce
the production of A peptides and inhibit the secretion
of soluble APP by human neuronal and extraneuronal
cells in vitro [186].
These findings lend support to the hypothesis that
T lymphocytes activated peripherally may cross the
BBB and secrete IFN- and other cytokines, interact
with microglia, and influence the neurodegenerative
processes involved in AD. Thus, T cells may be an
important link between the systemic adaptive immune
system and the innate immune system in the AD brain.
Infection-induced acute or chronic inﬂammation
exacerbates tau pathology in vivo
Sy et al. demonstrated that acute inflammation
induced by viral infection or chronic inflammation
induced by bacterial LPS resulted in AD-like pathol-
ogy in animal brains using the triple transgenic AD
mouse model (3xTg-AD). Aged 3xTg-AD and non-
Tg mice infected with a single dose of mouse hepatitis
virus (MHV) by injection into the hippocampus devel-
oped similar acute neuroinflammatory responses with
increased infiltration into the brain by macrophages,
CD4+ T cells, CD8+ T cells, and activation of
microglia. After viral clearance at 2 and 4 weeks
post-infection, MHV-infected 3xTg-AD mice showed
Fig. 6. The Lynch Hypothesis: T-cell lymphocytes infiltrate the brain and secrete IFN- which induces microglia activation and contributes
to neurodegeneration in AD. Proposed sequence of events leading to amyloid pathology and microglial activation in AD. T lymphocytes
cells activated peripherally cross the BBB and secrete IFN- and other cytokines, interact with microglia, and influence the neurodegenerative
processes involved in AD. Figure from Lynch MA (2014) The impact of neuroimmune changes on development of amyloid pathology; relevance
to Alzheimer’s disease. Immunology 141, 292-301 [167]. Copyright 2014. Reprinted with permission from John Wiley and Sons, Inc. and
Marina Lynch.
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a marked increase in phosphorylated tau protein lev-
els in the brain. In addition, increased activation of
GSK-3, one of the enzymes that phosphorylates tau
protein, was found. This effect was not seen in MHV
infected non-Tg mice. Sustained brain inflammation
was induced in 3xTg-AD aged mice by intraperi-
toneal injection of lipopolysaccharide, which is an
outer membrane Gram-negative bacterial endotoxin
that simulates bacterial infection. Injection of LPS
twice weekly for 6 weeks resulted in significant ele-
vation of phosphorylated tau protein levels, increased
GSK-3 activity, and cognitive decline compared with
saline injected 3xTg-AD aged control mice. Based
on these findings, the authors suggest that certain
microbial infections may act as comorbid factors in
the pathogenesis of AD by inducing inflammation,
increasing levels of phosphorylated tau proteins, and
exacerbating cognitive decline [187].
Infectious burden is associated with systemic
inﬂammation and serum Aβ levels in AD
Bu and co-workers studied IB, serum cytokine, and
A levels, and cognition in 128 AD patients and 135
healthy controls. IB consisted of serum antibody levels
to CMV, HSV-1, B. burgdorferi, C. pneumoniae, and
H. pylori. Total IB, bacterial burden, and viral burden
were independently associated with AD after adjusting
for age, gender, education, APOE genotype, and other
comorbidities. They found a significant association
between AD and an increasing number of pathogens
to which an individual had been exposed, with an OR
of 3.988 in patients seropositive for 4-5 pathogens
compared with those seropositive for 0–2 pathogens.
Furthermore, higher IB was associated with higher
serum A levels in both AD and healthy controls with
seropositivity to 3 or more pathogens. There were sig-
nificantly higher serum levels of IFN-, TNF-a, IL-1,
and IL-6 in participants seropositive for 4-5 pathogens
than those seropositive for 0–2 pathogens when includ-
ing all cases. AD patients seropositive to 4-5 pathogens
exhibited significantly higher levels of IFN-, TNF-,
and IL-6 when compared with AD patients seroposi-
tive to 0–2 pathogens. The authors suggest that higher
levels of IB may promote the development of AD by
infection-induced inflammation and elevated A levels
[188].
APOLIPOPROTEIN E OVERVIEW
Apolipoprotein E (ApoE) is a 299 amino acid pro-
tein component of lipoproteins. The primary metabolic
role for ApoE is to shuttle and distribute lipids from
one tissue or cell type to another and to regulate
lipid metabolism [189]. Various ApoE isoforms appear
to play a role in disease susceptibility and outcome
of certain infections, with evidence also supporting
involvement in immune regulation [189]. The liver
synthesizes the majority of ApoE; however, 20–40%
of ApoE is produced by extra-hepatic cells including
glial cells [190] and neurons [191].
ApoE associates with lipoproteins including VLDL,
LDL, and HDL during systemic transport of triglyc-
erides and cholesterol and is a primary carrier of
lipids across the BBB into the brain [190]. When
carrying lipids, ApoE binds to members of the low
density lipoprotein receptor (LDLR) family [191].
A secondary proposed ApoE binding site involves
the heparan sulphate proteoglycan (HSPG)/LDL-C
receptor-related protein pathway [192].
The human APOE gene is located on chromosome
19 as a single gene locus with three major allele iso-
forms designated 4, 3, and 2 [189]. APOE allele
frequencies vary between ethnicities, with the APOE-
ε4 allele variant occurring at a frequency of 5–30%,
the APOE-ε3 allele variant at 50–90%, and the APOE-
ε2 allele variant at 0–15% [190]. The corresponding
products of these alleles are the ApoE isoforms named
ApoE4, ApoE3, and ApoE2. The 6 resultant ApoE
phenotypes include 3 homozygous phenotypes (E4/4,
E3/3, and E2/2) and 3 heterozygous phenotypes (E4/3,
E4/2, and E3/2) [190].
The APOE-ε4 allele impacts outcomes in certain
infections
As discussed above, Itzhaki demonstrated increased
risk of AD by a factor or 12 in APOE-ε4 carriers
who have HSV-1 in the brain [49]. Patients with the
APOE-ε4 allele had a higher rate of oral herpetic
lesions compared to non-APOE-ε4 allele carriers with
a relative risk of 4.64 [193]. Transgenic APOE4 mice
infected with HSV-1 demonstrate higher CNS viral
loads compared with APOE3 [51]. HSV-1 binds to
HSPG located on the target cell membrane to facili-
tate entry into the cell [194]. Itzhaki et al. suggest that
ApoE4 may compete with HSV-1 for binding to cell
surface HSPG receptors, and that ApoE4 is less com-
petitive than ApoE3 or ApoE2, allowing more virus
particles to gain entry into the cell [191].
C. pneumoniae elementary bodies bind to human
astrocytoma cells possessing the APOE-ε4 allele at
levels 3-fold higher than non-APOE-ε4 allele bearing
cells. A separate line of astrocytoma cells transfected
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with plasmids expressing the 4 coding sequence
had 3-fold more C. pneumoniae elementary body
attachment than astrocytoma cells encoding ApoE3.
These findings demonstrate that expression of ApoE4
enhances attachment of C. pneumoniae elementary
bodies to target host cells, which may enhance infec-
tivity [195].
APOE-ε4 allele carriage is associated with a reduced
risk of acquiring chronic hepatitis C virus (HCV) [190,
196]. Carriage is also protective against severe liver
disease caused by HCV [197]. The exact mechanism
for this protective effect has yet to be elucidated;
however, HCV associates with serum lipoproteins
including apoE to enter cells via the LDLR [198].
The expression of LDLR on the cell surface of hepato-
cytes is inversely related to the concentration of LDL
in serum [199]. One hypothesis suggests that a higher
serum LDL concentration in APOE-ε4 carriers leads to
a lower LDLR expression, which potentially decreases
virus entry and spread between hepatocytes [197].
Corder and colleagues phenotyped sera from HIV
patients for ApoE and found that patients who
possessed a single copy of the ApoE4 isoform had
significantly higher rates of dementia and peripheral
neuropathy compared to those who were ApoE4 neg-
ative [200]. Burt et al. demonstrated that HIV positive
patients with the APOE-ε4/4 genotype have both
accelerated disease progression and progression to
death compared to APOE-ε3/APOE-ε3 carriers. An
association between APOE-ε4/4 genotype and HIV-
associated dementia was not confirmed in this study.
However, using an in vitro cell model with specialized
HeLa cells, the authors found that the HIV infection
rate was significantly higher in the presence of ApoE4
compared with ApoE3 [201].
The target cells of HIV include CD4+ T-cells,
macrophages, and microglia cells. HIV initiates entry
into the cell by attaching to the HSPG receptor on
the target cell membrane [190]. HIV envelope gly-
coproteins then bind to the CD4 receptor. Fusion to
the cell membrane requires cholesterol in HIV parti-
cles and lipid rafts, which are cell membrane micro
domains enriched in certain lipids, cholesterol and
proteins [190]. The mechanism by which ApoE iso-
forms impact HIV disease outcomes is not known.
Research has focused on the differential effects of
ApoE isoforms on HIV particle binding activity and
uptake involving the LDL-R and the HSPG recep-
tors [190]. One proposed mechanism is that ApoE4
may be less competitive compared with HIV at the
target cell HSPG receptor than ApoE3 or ApoE2 result-
ing in increased HIV cell entry [190]. An additional
hypothesis is that ApoE4 on the HIV viral enve-
lope promotes HIV binding activity at the low-density
lipoprotein receptor of the target cell [190].
APOE-ε4 allele is associated with enhanced
human innate immune responses
Gale et al. demonstrated that carriage of the APOE-
4 allele is associated with enhanced in vivo innate
immune responses in human subjects [202]. Whole
blood from healthy genotyped APOE-ε3/APOE-ε4
volunteers exposed ex vivo to TLR2, TLR4, or TLR5
ligands induced significantly higher levels of TNF-
than blood from APOE-ε3/APOE-ε3 carriers. Blood
from APOE-ε3/APOE-ε4 carriers also induced sig-
nificantly higher levels of IL1-, IL-6, IFN-, and
additional cytokines and chemokines after exposure
to TLR2 or TLR4 when compared with blood from
APOEε3/APOEε3 carriers. No difference was seen
between the two ApoE phenotypes regarding produc-
tion of anti-inflammatory compounds IL-4 and IL-1
receptor antagonist. Thus, ApoE4 is associated with
a broad pro-inflammatory response to TLR cascades.
Human APOE-ε3/APOE-ε4 subjects exposed to an
intravenous LPS challenge demonstrated enhanced
immune responses with significantly higher plasma
levels of TNF- and greater sustained body tem-
peratures compared with APOE-ε3/APOE-ε3 subjects
[202].
Differences in monocyte lipid rafts have been found
in APOE-ε3/APOE-ε4 human peripheral blood mono-
cytes compared with APOE-ε3/APOE-ε3 monocytes
[202]. Lipid rafts within the cell membrane organize
cellular signaling events [203]. Several TLR cascades
are initiated in lipid rafts, which and are enhanced by
cholesterol loading [202]. ApoE4 is less efficient at
inducing cholesterol efflux and removing cholesterol in
mouse macrophages [204]. Gale et al. used a fluoro-
taggedcholeratoxinBsubunit lipidraftprobetostudy in
vitro CD14 monocytes. Augmented lipid raft assembly
in APOE-ε3/APOE-ε4 monocytes compared to APOE-
ε3/APOE-ε3monocyteswasdemonstrated.Theauthors
suggest that ApoE4 may enhance cholesterol loading in
monocyte lipid raft structures due to decrease in choles-
terol efflux, which in turn enhances TLR responses with
pro-inflammatory consequences [202].
The APOE-ε4 genotype with resultant ApoE4 phe-
notype appears to influence disease outcome for
several infections and elevate the pro-inflammatory
innate immune response. Evidence supporting ApoE4
associated enhanced infectivity and brain infiltration
would explain the increased risk of AD in patients who
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are co-factor positive for HSV-1 in the brain and the
APOE-ε4 allele [50]. Increased binding of C. pneu-
moniae elementary bodies to APOE-ε4 target host
cells suggests increased infectivity as a mechanism to
explain elevated numbers of C. pneumoniae infected
cells in APOE-ε4 allele carrier AD brains [123].
An increased ApoE4 associated pro-inflammatory
response may contribute to AD pathogenesis by both
increasing BBB permeability and elevating levels of
pro-inflammatory cytokines.
THE BLOOD-BRAIN BARRIER AND THE
AD PATHOGEN HYPOTHESIS: BBB
IMPAIRMENT IN AD
Breakdown of the BBB with increased permeability
is involved in the pathophysiology of AD [205, 206].
Postmortem studies have shown BBB damage in AD
with accumulation of blood-derived proteins including
albumin, fibrinogen, thrombin, and immunoglobulins
in the hippocampus and cortex [207]. BBB breakdown
appears to be an early event in the aging human brain
that begins in the hippocampus and may contribute to
cognitive impairment [207]. Montagne and collabo-
rators used an advanced dynamic contrast enhanced
MRI protocol with high spatial and temporal reso-
lutions to quantify regional BBB permeability in the
living human brain. In doing so, they demonstrated an
age-dependent BBB breakdown in the hippocampus,
an area of the brain affected early in AD. The BBB
breakdown in the hippocampus and its CA1 and dentate
gyrus subdivisions worsened with MCI that correlated
with injury to BBB-associated pericytes, as shown by
the CSF analysis [207]. Evidence suggests that pro-
inflammatory cytokines, A, and APOE4 genetics are
contributing factors in the breakdown of the BBB
[212–214], with data indicating pathogen association
and interactions with each of these factors as previously
discussed.
Composition of the blood-brain barrier
The BBB is located at the level of the cerebral
microvasculature and serves as the largest interface
for blood-brain exchange [208]. The BBB forms a
physical, enzymatic, and transport barrier between the
vasculature and the brain parenchyma [209]. Brain
microvascular endothelial cells (BMECs) line cere-
bral blood vessels to form a barrier on the endothelial
side of the vessel. Pericytes and astrocyte end feet
form a continuous barrier in association with the base-
ment membrane on the adluminal vessel surface [210].
BMECs form intercellular contacts via two types
of junctions known as adherens junctions (AJs) and
tight junctions (TJs). TJs in BMECs are composed
of the membrane proteins occludin, claudins, junc-
tional adhesion molecules, and cell-selective adhesion
molecules, which are linked to the actin cytoskele-
ton by cytoplasmic proteins ZO-1, ZO-2, ZO-3, and
cingulin [210]. AJs contain cadherins bound to actin
microfilaments by a submembranous zone of catenins
[211]. These junctions promote high transendothelial
electrical resistance that restricts paracellular perme-
ability [210]. This in turn blocks the transport of
a wide range of molecules and regulates the pas-
sage of ions, macromolecules, and polar molecules
from the systemic circulation [210]. Endothelial cells
of the BBB lack fenestrations and have a reduced
number of pinocytotic vesicles, which restricts trans-
cellular flux [208]. However, some molecules and
solutes are transported across the BBB by various
mechanisms including transporters, receptor and/or
adsorption-mediated transcytosis, and passive diffu-
sion [208].
The blood-brain barrier: Pathogens and
neuroinﬂammation
Certain pathogens may cross the BBB either tran-
scellularly, paracellularly, or by means of infected
phagocytes by a Trojan horse mechanism [215]. N.
meningitidis exemplifies a bacterium which crosses the
BBB transcellularly [215]. Evidence suggests that B.
burgdorferi may cross the BBB paracellularly [215],
whereasC. pneumoniaemay cross by way of the “Troj-
ganhorse”mechanism,intracellularywithinmonocytes
or macrophages [108, 109]. Other pathogens including
HSV-1 cross the BBB via the olfactory nerve and/or
trigeminal nerve [5, 208]. In addition to pathogens that
cross the BBB directly, blood-born cytokines including
IL-1, IL1-, IL-6, TNF-, and others can cross BBB
via transport systems and act directly on brain tissue as
demonstrated in animal models [209, 216].
CNS infections and other diseases associated with
elevated pro-inflammatory cytokine levels increase the
permeability of the BBB [214]. Cytokines such as IL-1
act on brain endothelial cells to increase the expression
of endothelial adhesion molecules and chemokines,
including CC chemokine ligand-2 (CCL2), selectins,
and intracellular adhesion molecule-1 (ICAM-1),
which contribute to BBB permeability [217]. Pro-
inflammatory cytokines also increase expression of
matrix metalloproteinases (MMPs), which degrade
extracellular matrix components in the endothelial
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basement membrane and tight junctions, resulting in
increased BBB permeability [218, 219]. Labus et al.
found that IL-1 induced an inflammatory response
and breakdown of the endothelial layer in an in vitro
BBB model. IL-1 induced endothelial cells expres-
sion of adhesion molecule ICAM-1, IL-6, IL-8, and
TNF- . IL-1 also reduced the expression of tight
junction protein ZO-1. Increases in both paracellular
permeability and leukocytes crossing the cell layer of
the BBB model were demonstrated [214].
Aβ and the blood-brain barrier
Evidence indicates that A and BBB disruption
interact to mutually promote their effects on AD patho-
genesis [213]. Accumulation of A in the brain may
contribute to the breakdown of the BBB. Conversely,
dysfunction of the BBB may result in A accumula-
tion due to BBB leakage or decreased clearance [213].
P-glycoprotein, an efflux pump highly expressed on
the luminal surface of brain capillary endothelial cells
of the BBB, has been shown to transport A from the
brain to the blood [220, 221]. Decreased function of
this transporter has been reported in AD brains [221].
A42 is able to modify the expression of TJs and alter
the functionality of an epithelial BBB in vitro model
[222]. In addition, A accumulation has been shown
to cause BBB dysfunction by inducing endothelial cell
toxicity both in vitro and in vivo in animal studies,
human studies, and human postmortem studies [223].
Soluble A also stimulates BBB endothelial cells to
increase monocyte adhesion, which has been hypoth-
esized to increase monocyte permeability across the
BBB leading to monocyte transmigration into the brain
parenchyma [223].
APOE-ε4 and the blood-brain barrier
Animal models support a role for genetic suscep-
tibility in the breakdown of the BBB. Using APOE
transgenic mice, Bell et al. found that expression of
ApoE4 and lack of murine ApoE lead to BBB break-
down by activating a pro-inflammatory cyclophilin A
(CypA)-nuclear factor-B-MMP-9 pathway in peri-
cytes through a lipoprotein receptor. This was followed
by neuronal uptake of neurotoxic proteins and reduc-
tions in microvascular and cerebral blood flow. Break-
downintheBBBprecededneuronaldysfunctionandthe
initiation of neurodegenerative changes [224].
In a postmortem study, Halliday and colleagues
demonstrated accelerated pericyte degeneration in AD
APOE-ε4 carriers > AD APOE-3 carriers > non-AD
Fig. 7. Quantification of HSV-1 proteins (A), amyloid- (B), and
abnormal tau phosphorylation (C) in HSV-1-infected cells after acy-
clovir treatment. HSV-1 infected vero cell cultures treated with
0M, 50M, 100M, or 200M acyclovir (ACV). ACV sig-
nificantly inhibited replication of HSV-1 as shown by a decrease
in HSV-1 proteins (A). A in cell cultures was reduced by
70% at a 200M concentration of acyclovir (B). Abnormal tau
phosphorylation was reduced nearly 100% at a 200M concen-
tration of acyclovir (C). p < 0.0001 compared to controls at all
ACV concentrations for A and C and at 100M and 200M
ACV concentrations for B. Graph from Wozniak MA et al.
(2011) Antivirals reduce the formation of key Alzheimer’s disease
molecules in cell cultures acutely infected with Herpes simplex
virus type 1. PLoS One 6, e25152 [166]. Copyright 2011. Reprinted
under the terms of the Creative Commons Attribution License,
(http://creativecommons.org/licenses/by/2.0) and permission from
Ruth Itzhaki.
controls, which correlated with the magnitude of
BBB breakdown as measured by permeability to
immunoglobulin G and fibrin. Accumulation of CypA
and MMP-9 in pericytes and endothelial cells was
greater in AD subjects who were APOE-4 carriers
than those who were APOE-3 carriers. Levels of
the ApoE lipoprotein receptor, low-density lipoprotein
receptor-related protein-1 (LRP1), were reduced in AD
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APOE-4 and APOE-3 carriers. This data suggests
that possession of APOE-4 leads to accelerated peri-
cyte loss and enhanced activation of LRP1-dependent
CypA-MMP-9 BBB-degrading pathway in pericytes
and endothelial cells. These processes mediate BBB
damage, which is more severe in AD APOE-4 carriers
than AD APOE-3 carriers [212].
POTENTIAL ANTIMICROBIAL
TREATMENTS FOR AD CLINICAL TRIALS
Treatment of HSV-1: Acyclovir and valacyclovir
Acyclovir decreases HSV-1-induced A accumu-
lation in cultured neuroblastoma cells [166]. A in
cell cultures was reduced by 70% at a 200M con-
centration of acyclovir. In addition, acyclovir inhibits
HSV-1-induced abnormal tau phosphorylation in vitro.
Abnormal tau phosphorylation was reduced nearly
100% at a 200M concentration of acyclovir (Fig. 7)
[166]. Acyclovir decreased A by reducing cellular
viral spreading and decreased tau phosphorylation by
interfering with viral replication [166]. Penciclovir and
foscarnet, which also inhibit viral DNA replication,
were shown to reduce phosphorylated tau and A,
with foscarnet being less effective than acyclovir and
penciclovir [166].
Acyclovir is a nucleoside analogue that interferes
with HSV-1 replication and reactivation. Viral thymi-
dine kinase is required to convert acyclovir into
acyclo-guanosine monophosphate. Subsequently, the
monophosphate form is converted to the active tri-
phosphate form by cellular kinases. As a substrate,
acyclo-guanosinetriphosphateisincorporatedintoviral
DNA, resulting in premature chain termination. Acy-
clovir is able to cross the BBB [225]. The drug would
directly target a potential cause of AD, act on infected
cells only, and would not affect the normal metabolism
of infected neurons [166].
Acyclovir is FDA approved and widely used for the
treatment of HSV infections. The side effect profile is
mild; however it would be necessary to monitor renal
function [225]. Rarely, treatment is complicated by
reversible neuropsychiatric symptoms occurring more
frequently in patients with pre-existing renal impair-
ment [225].
Valacylovir is the biodrug of acyclovir. Following
oral administration, valacyclovir is rapidly hydrolyzed
to acyclovir via first-pass intestinal and hepatic
metabolism [225]. Valacyclovir has better oral absorp-
tion than acyclovir and is able to cross the BBB as acy-
clovir following hydrolysis [226]. Oral valacyclovir
has been used to successfully treat herpes simplex
encephalitis [227]. In a multiple sclerosis trial eval-
uating HHV-6, valacyclovir at a dose of 3 grams per
day for 2 years was shown to be safe with no patient
discontinuation due to side effects or toxicity [228].
Both acyclovir and valacyclovir have been found safe
during long-term use in patients being treated for
HSV suppression [229]. Furthermore, resistance rates
are low (<0.5%) among immunocompetent patients
[229].
Prasad et al. conducted a clinical trial involving 24
HSV-1 IgG seropositive schizophrenia patients who
were treated with valacyclovir 1.5 grams twice daily
for 18 weeks. The treatment group demonstrated sig-
nificantly improved cognition, specifically in verbal
memory, working memory, and visual object learning,
comparedwiththeHSV-1IgGseronegativeschizophre-
nia control group. Both treatment and control groups
weretreatedwithanti-psychoticmedication.Whilepsy-
chotic symptoms did not improve with valacyclovir, the
study did show that valacyclovir improved cognition
in a select group of HSV-1 exposed neuropsychiatric
patients [230].
Intravenous immunoglobulin (IVIG)
Natural antibodies to A in human IVIG promote
microglial recognition and removal of natively formed
human A deposits ex vivo in an APP/PS1 mouse
model of AD [231]. IVIG administered peripherally
in vivo crossed the mouse BBB, reaching highest
concentrations in the hippocampus. The antibodies
bound selectively to A deposits and co-localized with
microglia [231]. Preclinical and small clinical stud-
ies treating early stage AD patients with IVIG showed
decreases in CSF A levels and increases in serum
A levels compared to baseline, with reductions in
cognitive decline compared to controls [232, 233].
However, the Gamma Globulin Alzheimer’s Partner-
ship (GAP) study, a large double blind IVIG clinical
trial treating mild to moderate AD patients, did not
meet primary outcome objectives regarding cognitive
function and activities of daily living. Biomarker stud-
ies did indicate dose dependent increases in plasma and
CSF immunoglobulins and decreases in plasma A42
levels [234].
IVIG has antiviral activity against HSV-1 and can
neutralize extracellular virus [235]. Additionally, IVIG
in conjunction with lymphocytes is able to destroy
cells infected with HSV-1 [235–237]. IVIG (Privigen)
treated HSV-1 infected Vero cells demonstrated sta-
tistically significant reductions of A, phosphorylated
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tau, and HSV-1 proteins [238]. Privagen appeared to
prevent viral entry into cells and act synergistically
with acyclovir, leading the authors to suggest that the
combination of IVIG and acyclovir may be beneficial
in the treatment of AD [32, 238].
HSV-1 vaccine
Lin and coworkers showed that a vaccine of mixed
HSV-1 glycoproteins had a protective effect against
HSV-1 infection of mouse brain. The vaccine signif-
icantly reduced HSV-1 latency in the CNS of mice
that had been infected peripherally with HSV-1 [239].
Although not yet developed, a human vaccine for HSV-
1 administered to prevent HSV-1 infiltration into the
brain might prevent some cases of AD [239].
Treatment of CMV, EBV, and HHV-6
Anti-viral therapy for asymptomatic CMV infection
in immunocompetent patients is not feasible because
of toxicity, limited number of approved drugs, and the
potential for drug resistance [82]. Thus, there is no
available suppressive therapy for CMV comparable
to the usage of valacyclovir or acyclovir for HSV
suppression. Ganciclovir (GCV) and valganciclovir,
the oral prodrug of GCV, are nucleoside analogues.
GCV is phosphorylated to its active form in CMV-
infected cells. These medications are currently the
most commonly prescribed drugs for the preven-
tion and treatment of CMV in immunocompromised
patients [240]. Although limited, current evidence sug-
gests that targeted antiviral therapy with GCV or
valganciclovir is appropriate for severe CMV disease
in immunocompetent adults [241]. There are no FDA
approved medications for the treatment of EBV, and
anti-viral therapy is generally ineffective for this virus
[242]. No therapies are approved for the treatment of
HHV-6 currently; however, small studies and individ-
ual case reports have reported intermittent success with
drugs such as cidofovir, GCV, and foscarnet [243]. To
date there are no FDA approved vaccines for CMV,
EBV, or HHV-6 [240].
Treatment of Chlamydophila pneumoniae
Acute C. pneumoniae infections are susceptible to
antibiotics that interfere with DNA and protein syn-
thesis, including tetracyclines, macrolides, quinolones,
and rifamycins [110]. All of these antibiotics cross
the BBB except for the macrolides [244]. C. pneu-
moniae becomes spontaneously persistent following
infection of monocytes [112]. C. pneumoniae within
infected lymphocytes in vitro demonstrated resis-
tance to single antibiotics including minocycline and
tosufloxacin and did not show uniform susceptibil-
ity within infected monocytes [245]. Nine months
of combination doxycycline and rifampin were used
in a successful clinical trial as treatment for chronic
Chlamydia-induced reactive arthritis. This study sug-
gests that persistent chlamydia infection responds
poorly to single antibiotic therapy but appears to be
susceptible to combination antibiotic regimens [246].
Tetracyclines possess both immunomodulatory and
antiapoptotic properties [247] and have been shown to
be anti-inflammatory and neuroprotective in various
models of neurodegenerative disease [248]. Tetra-
cycline and doxycycline exhibit anti-amyloidogenic
activity in vitro by inhibiting the self-aggregation
capacity of A42 and disassembling pre-formed A42
fibrils [249]. The semi-synthetic, second generation
tetracycline analog minocycline inhibited increases
in p-eIF2 and reduced neuronal cell death in A42
peptide treated nerve growth factor-differentiated
rat pheochromocytoma (PC12) cells in vitro [161].
Minocycline also reduced neuronal cell death and
attenuated deficits in learning and memory after A42
infusion in a rat model of AD [161].
Rifampin crosses the BBB [244, 250] and attenuates
all chlamydial gene transcription [246]. Rifampin-
induced upregulation of LRP1 and p-glycoprotein at
the BBB enhances A clearance from the mouse brain
[251].
In a clinical trial, Loeb et al. treated probable AD
patients diagnosed with mild to moderate dementia
with doxycycline and rifampin versus placebo for 3
months. There was significantly less decline in cog-
nition as measured by the Standardized Alzheimer’s
Disease Assessment Scale cognitive subscale at 6
months in the antibiotic treatment group compared to
the placebo group [252]. In a clinical trial by Molloy
and colleagues, mild to moderate AD patients were
treated for 12 months with doxycycline and rifampin.
These drugs, given both alone or in combination,
had no effect on cognition or function [253]. Pre-
clinical AD patients and biomarker endpoints were
not assessed in this study. In addition, these med-
ications have not been tested in combination with
valacyclovir.
Treatment of spirochetes
The CNS infection Lyme neuroborreliosis caused
by the spirochete B. burgdorferi has been successfully
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treated in clinical trials with 10–14 days of intra-
venous ceftriaxone or oral doxycycline [254, 255].
In one trial, 79% of the ceftriaxone-treated patients
and 72% of the doxycycline-treated patients had com-
pletely recovered by 6 month follow-up. Ceftriaxone
and oral doxycycline used as single agents were found
to be effective, safe, and convenient for treatment of
Lyme neuroborreliosis [254]. Abramson et al. studied
the bactericidal activity of antimicrobial agents in vitro
for 17 strains of treponemes. Most treponemes, includ-
ing human oral spirochetes such as T. dentolytica, were
sensitive to tetracycline, doxycycline, and cephalothin
[256].
Treatment of periodontal pathogens
Improved oral hygiene and meticulous dental care
may be beneficial for patients with dementia. Kikutani
et al. studied the effects of oral care in a group of nurs-
ing home vascular dementia and AD patients. The oral
care group had a high level of dental care, as nurses and
caregivers cleaned the patients’ teeth and mouth with a
toothbrush for approximately 5 minutes after each meal
for one year. The oral care group had significantly less
decline in MMSE scores compared to the non-oral care
group at six months and one year [257].
Systemic antibiotics are widely used in the treatment
of periodontal infections; however, clear guidelines
for the use of systemic antibiotics to treat periodon-
titis in general clinical practice are not yet available
[258, 259]. Adjunctive antibiotic treatment in mod-
erate periodontal disease for 14 days with either
amoxicillin or metronidazole in addition to traditional
scaling and root planing has been shown to markedly
reduce bacterial counts for pathogenic species includ-
ing B. forsythus, P. gingivalis, and T. denticola,
which remained lower than baseline at one year
post-treatment [259]. Several clinical trials treating
patients with mild to moderate periodontal disease
have shown microbiological and/or clinical benefits by
using azithromycin or metronidazole combined with
scaling and root planing or pocket reduction surgery
when compared to scaling and root planing alone
[260–262], or surgery alone [263]. Subantimicrobial
dose doxycycline (20 mg doxycycline twice daily) has
also been used successfully to treat periodontitis [247].
Feres et al. extensively reviewed randomized clini-
cal trials performed over the last decade involving
antibiotic treatment of periodontitis where advanced
microbial diagnostic testing had been performed.
Patients treated with adjunctive antibiotic therapy had
improved microbiological and clinical outcomes [258].
The authors recommended that patients with advanced
or very advanced periodontitis should be treated with
the adjunctive use of metronidazole or combination
metronidazole plus amoxicillin for 14 days in addition
to traditional scaling and root planing [258]. Antibiotic
treatment does not appear to create lasting changes in
the percentage of resistant isolates or sites harboring
resistant species [260, 264].
Treatment of Helicobacter pylori
Treatment of H. pylori involves triple or quadru-
ple regimens using a proton pump inhibitor such
as omeprazole plus various combinations of amoxi-
cillin, Clarithromycin, metronidazole, and tetracycline
taken orally for 7 to 14 days. Sequential, concomi-
tant, or hybrid regimens are chosen depending on
resistance rates and other clinical factors [265, 266].
Clarithromycin and metronidazole resistance has been
increasing in certain populations. Levaquin triple based
and bismuth quadruple based regimens have been used
successfully to treat resistantH. pylori. Patient-specific
therapy is based on factors such as cost, allergy history,
and known or suspected patterns of resistance [266].
Treatment success rates with current regimens are vari-
able, ranging from 50% to over 95% in clinical trials
depending on factors such as length of treatment, rates
of antibiotic resistance and patient specific cytochrome
P450 2C19 genotype [265].
Kountouras et al. evaluated AD patients with gas-
tric biopsy-proven H. pylori infection. Patients were
treated with combination omeprazole, clarithromycin,
and amoxicillin triple based therapy to eradicate
H.pylori from the gastric mucosa. At the 2-year clinical
endpoint, cognitive (MMSE and Cambridge Cogni-
tive Test) and functional (Functional Rating Scale
for Symptoms of Dementia) parameters significantly
improved in the subgroup of AD patients with suc-
cessful H. pylori eradication, but not in the subgroup
of AD patients in which H. pylori eradication was
not achieved [152]. In another clinical trial, success-
ful treatment and eradication of H. pylori in a group
of probable AD patients was associated with a sig-
nificantly lower 5-year mortality risk than a control
group of probable AD patients who did not achieve
eradication of the bacterium [267].
CONCLUSION
Evidence supports the hypothesis that pathogens
interact with susceptibility genes and are causative in
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AD. Pathogen induced neurodegeneration occurs by
both direct effects on brain cells and indirect inflam-
matory and oxidative effects. HSV-1, C. pneumoniae,
and spirochetes are able to infect the brain and induce
formation of A and hyperphosphylated tau proteins.
Chronic CNS infections lead to glial cell activation,
resulting in neuroinflammation and neuronal apopto-
sis. Peripheral infections including CMV, periodontal
pathogens, andH.pylori induce systemic inflammation
with elevated levels of pro-inflammatory molecules.
Pathogen induced pro-inflammatory cytokines are
transported across the BBB into the brain where
they induce CNS inflammation and contribute to
AD pathology in genetically susceptible individu-
als. In addition, pathogen induced pro-inflammatory
cytokines and A interact with genetic susceptibil-
ity factors to damage the BBB, resulting in increased
BBB permeability. Chronic CMV infection with
reactivation in peripheral blood or organ systems
induces systemic activation of IFN--producing T
cells, which may enter the brain and contribute to
the pathogenesis of AD. CMV also plays a role in
immunosenescence, which damages the immune sys-
tem and is associated with the reactivation of other
Herpesviridae such as HSV-1. Thus, in addition to
direct pathogen effects, AD pathogenesis results from
interactions involving both the innate and adaptive
immune responses to both CNS and peripheral sys-
temic pathogens.
As proposed, the AD pathogen hypothesis would
explain the multiple epidemiological studies showing
increased risk for development of cognitive impair-
ment and AD in patients with various CNS infiltrative
and systemic chronic infections. Peripheral viral
reactivation with resultant systemic inflammation is
a potential mechanism involved in the association
between HSV-1 seropositivity and cognitive impair-
ment in younger patients ages 6 to 16 as found by Tarter
et al. [87]. Systemic HSV-1 induced inflammation may
also explain the association between HSV-1 positivity,
cognitive impairment, and neurodegeneration on MRI
in relatively younger schizophrenic patients as demon-
strated by Schretlen et al. [34]. Younger subjects have
been shown not to have HSV-1 in the brain [107] so
presumably, the patients in these studies did not have
direct HSV-1 CNS infiltration by the virus. Limited
studies to date have failed to detect HSV in postmortem
brain tissue from patients with schizophrenia as well
[268], including one study using nested PCR [269].
The APOE-4 allele with resultant ApoE4 phe-
notype impacts the pathophysiology of AD by
increasing the pathogen load in the brain, specifically
for HSV-1 and C. pneumoniae. ApoE4 also inter-
acts with pathogens to enhance the human innate
pro-inflammatory response and contributes to the
breakdown of the BBB.
HSV-1 may be a primary CNS infiltrative pathogen
in the pathophysiology of AD. There is substantial
evidence for HSV-1 causation in AD involving studies
in epidemiology, neuropathology, and molecular
biology as cited in this review. There is the high
prevalence of HSV-1 in both elderly normal brains
and AD brains [4, 41] (Table 1) and the presence of
both HSV-1 in brain and carriage of the APOE-4
allele significantly increases the risk for sporadic AD
[49]. Data for both C. pneumoniae and spirochetes
(Table 3 and Fig. 3) shows a high prevalence of these
pathogens in AD brains only [5, 126], suggesting
that secondary C. pneumoniae and/or spirochete
infection of brain may occur after HSV-1 and other
co-factors have already initiated AD pathogenesis.
Additional studies need to be done to confirm this
hypothesis.
A comprehensive antimicrobial treatment strategy
for AD must be developed and tested in clinical
trials focusing on pre-clinical or early onset AD.
Itzhaki [270] and Strandberg [28] have proposed a
randomized controlled antiviral clinical trial using
oral valacyclovir. The initial study would test the
concept that HSV-1 in APOE-4 carriers is causative
in AD [80]. Additional AD clinical trials could then
evaluate the AD multi-pathogen hypothesis by testing
the effectiveness of valacyclovir combined with the
appropriate antibiotics used to treat spirochetes,
chronic persistent C. pneumoniae, and systemic AD
associated pathogens such as H. pylori and periodontal
infections.
Safe, effective, and less toxic treatments for
CMV and other Herpesviridae must be developed.
Antimicrobial medication in combination with anti-
inflammatory treatments may also be beneficial in the
treatment of AD. Vaccines against CMV, HSV-1, and
other Herpesviridae must be developed, as reducing
primary infection or reactivation may be useful in AD
prevention.
Treatment of HSV-1 and other pathogens present in
the AD brain and peripherally may be the most effi-
cacious way to reduce CNS inflammation. The goal
of such treatment would be to lower production of
pro-inflammatory molecules, reduce accumulation of
A, and lower the levels of hyperphosphorylated tau
proteins. Antimicrobial therapy could decrease neu-
ronal damage and apoptosis and ultimately aid in the
prevention and treatment of AD.
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